US20020182253A1 - Sustained-release microgranules containing diltiazem as active principle - Google Patents

Sustained-release microgranules containing diltiazem as active principle Download PDF

Info

Publication number
US20020182253A1
US20020182253A1 US09/998,911 US99891101A US2002182253A1 US 20020182253 A1 US20020182253 A1 US 20020182253A1 US 99891101 A US99891101 A US 99891101A US 2002182253 A1 US2002182253 A1 US 2002182253A1
Authority
US
United States
Prior art keywords
microgranules
layer
yed
active principle
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/998,911
Other versions
US6660296B2 (en
Inventor
Patrice Debregeas
Gerard Leduc
Pascal Oury
Pascal Suplie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHANTILLY BIOPHARMA LLC
Original Assignee
Ethypharm SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9485856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020182253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ethypharm SAS filed Critical Ethypharm SAS
Priority to US09/998,911 priority Critical patent/US6660296B2/en
Publication of US20020182253A1 publication Critical patent/US20020182253A1/en
Application granted granted Critical
Publication of US6660296B2 publication Critical patent/US6660296B2/en
Assigned to ETHYPHARM reassignment ETHYPHARM CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARM
Assigned to BIOVAIL LABORORATORIES INTERNATIONAL, S.R.L. reassignment BIOVAIL LABORORATORIES INTERNATIONAL, S.R.L. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LABORATORIES DES PRODUITS ETHIQUES ETHYPHARM
Assigned to GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT reassignment GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT SECURITY AGREEMENT Assignors: BIOVAIL INTERNATIONAL LABORATORIES (BARBADOS) SRL, BIOVAIL INTERNATIONAL LABORATORIES SRL
Assigned to BIOVAIL INTERNATIONAL LABORATORIES (BARBADOS) SRL, BIOVAIL INTERNATIONAL LABORATORIES SRL reassignment BIOVAIL INTERNATIONAL LABORATORIES (BARBADOS) SRL PATENT SECURITY RELEASE AGREEMENT Assignors: GOLDMAN SACHS LENDING PARTNERS LLC
Assigned to VALEANT INTERNATIONAL (BARBADOS) SRL reassignment VALEANT INTERNATIONAL (BARBADOS) SRL CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: BIOVAIL LABORATORIES INTERNATIONAL SRL
Assigned to CHANTILLY BIOPHARMA LLC reassignment CHANTILLY BIOPHARMA LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VALEANT INTERNATIONAL (BARBADOS) SRL
Assigned to VALEANT INTERNATIONAL BERMUDA reassignment VALEANT INTERNATIONAL BERMUDA CHANGE IN NAME AND COUNTRY OF INCORPORATION Assignors: VALEANT INTERNATIONAL (BARBADOS) SRL
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to novel forms of sustained-release (SR) microgranules containing Diltiazem as active principle.
  • SR sustained-release
  • Diltiazem is a calcium-antagonist benzothiazepine derivative which is useful for the treatment of arterial hypertension. It may be administered in various forms: tablets, injectable solutions or gelatin capsules containing sustained-release granules. The latter have the advantage of allowing the administration to be taken as a single dose required for daily treatment.
  • Diltiazem SR microgranules have been described in the prior art, the most advantageous being that described in patent application EP-A-0,149,920, comprising a core combining Diltiazem with a water-soluble organic acid, in particular fumaric acid.
  • a water-soluble organic acid in particular fumaric acid.
  • Diltiazem, or its pharmaceutically acceptable salts are sparingly soluble at neutral or basic pH, and the presence of a water-soluble organic acid has proven to be particularly important, making it possible to create a buffered acidic microenvironment, promoting both the dilution and the absorption of the Diltiazem in areas of the digestive tract where the pH is too high. It has, nevertheless, been observed that for these SR forms, the solubilization and absorption of Diltiazem were dependent on the absorption of food, and are different when uptake of the microgranules is carried out on an empty stomach or during meals.
  • the sustained release of the active principle is ensured by one or more layers coating the core of the microgranules, generally combining two types of film-forming polymer material, one being water-insoluble and the other water-soluble.
  • the present invention relates to a novel form of SR microgranules containing Diltiazem, or a pharmaceutically acceptable salt thereof, which is free of water-soluble organic acid, making it possible to obtain solubilization and absorption of the active principle which are at least equivalent to those obtained in the presence of an acid.
  • the present invention relates to a simple novel form of SR microgranules containing Diltiazem, which is easy to prepare.
  • microgranules according to the invention comprise a neutral granular support coated with an active layer comprising Diltiazem or a pharmaceutically acceptable salt thereof, a surfactant and a binder, and a layer which ensures sustained release of the active principle (referred to hereinbelow as the SR layer).
  • an active layer comprising Diltiazem or a pharmaceutically acceptable salt thereof, a surfactant and a binder, and a layer which ensures sustained release of the active principle (referred to hereinbelow as the SR layer).
  • microgranules in accordance with the present invention may be of several categories.
  • the first category is represented by microgranules whose SR layer ensures slow sustained release of the active principle.
  • the second category is represented by microgranules whose SR layer ensures rapid sustained release of the active principle.
  • the dissolution profile of each of these two types of microgranule is determined in vitro using water as dissolution medium, and gives the following specifications: Preferred Hours Dissolution Dissolution Rapid microgranules: 2 h 0-45% ⁇ 30% 6 h ⁇ 50% ⁇ 65% Slow microgranules: 12 h 0-60% ⁇ 30% 20 h ⁇ 50% ⁇ 45% Mixture: 1 h ⁇ 15% ⁇ 15% 6 h ⁇ 55% 25 ⁇ 55% 10 h 30-70% 30-60% 16 h 30-85% 55-85% 22 h — ⁇ 80%
  • the present invention also relates to a third category of microgranules resulting from the coating of the SR layer which ensures slow sustained release of the active principle, that is to say of the SR layer of microgranules of the first category above, from another active layer comprising:
  • these so-called “bilayer” microgranules consist, from the centre to the periphery, of a neutral granular support, of a first active layer, of an SR layer ensuring slow sustained release of the active principle contained in the first active layer, of a second active layer and of an SR layer ensuring rapid sustained release of the active principle contained in the second active layer.
  • a so-called protective coating or intercalating layer is applied to the microgranule between the SR layer ensuring slow sustained release of the active principle and the second layer of active principle.
  • the neutral granular support consists of any pharmaceutically acceptable neutral granular support, with an average diameter of between 0.4 and 0.9 mm, preferably 0.4 and 0.6 mm. These are preferably grains consisting of sucrose and starch in a weight ratio in the region of 75/25, such as those described under the name “Sugar Spheres” (Handbook of Pharmaceutical Excipients, 2nd Ed., The Pharmaceutical Press, London, 1994).
  • the hydrochloride is preferably among the pharmaceutically acceptable salts of Diltiazem.
  • the surfactant may be an anionic, nonionic, cationic or amphoteric surfactant. It is preferably an anionic surfactant.
  • anionic surfactants are alkali metal (C 10 -C 20 )alkyl sulphates, preferably sodium lauryl sulphate, alkali metal (C 10 -C 20 )alkyl sulphonates or alkali metal (C 10 -C 20 )alkyl benzenesulphonates.
  • alkali metal is preferably understood to refer to sodium or potassium.
  • the binder consists of any pharmaceutically acceptable binder which is useful for coating neutral granular supports, in particular pharmaceutically acceptable polymers such as the polyvinylpyrrolidones described under the name povidone (Handbook of Pharmaceutical Excipients, 2nd Ed., The Pharmaceutical Press, London, 1994), or hydroxypropyl methyl celluloses (HPMC), polyethylene glycols (PEG), etc.
  • pharmaceutically acceptable polymers such as the polyvinylpyrrolidones described under the name povidone (Handbook of Pharmaceutical Excipients, 2nd Ed., The Pharmaceutical Press, London, 1994), or hydroxypropyl methyl celluloses (HPMC), polyethylene glycols (PEG), etc.
  • the active layer comprising the Diltiazem may also comprise other common additives, such as a plasticizer.
  • the active principle/neutral granular support weight ratio is in the region of 4/1.
  • the term active principle is understood to refer to Diltiazem or the pharmaceutically acceptable salts thereof.
  • the active principle/surfactant weight ratio is advantageously between 99/1 and 95/5, preferably about 98/2.
  • the active principle/binder weight ratio is itself between 99/1 and 90/10, preferably in the region of 97/3.
  • the monolayer microgranules according to the invention preferably comprise the following components for the support and the active layer, the percentages being given on a weight basis for a total of 100: neutral granular support 20-25% active principle 70-75% surfactant 0.5-5% binder 0.5-10% plasticizer 0-5%.
  • the bilayer microgranules according to the invention preferably comprise the following components for the support and the active layers, the percentages being given on a weight basis for a total of 100: neutral granular support 10-20% active principle 75-85% surfactant 0.5-5% binder 0.5-10% plasticizer 0.5-5%.
  • Each SR layer consists of a coating agent which ensures the sustained release, optionally combined with one or more common additives, in particular a bioavailability adjuvant and/or a plasticizer and/or a lubricant.
  • the coating agent ensuring the sustained release is preferably a water-insoluble film-forming polymer, such as polymethacrylates (Handbook of Pharmaceutical Excipients, 2nd Ed., The Pharmaceutical Press, London 1994), in particular poly(ethyl acrylate, methyl methacrylate, trimethylammoniumethyl methacrylate chloride), which are marketed under the brand name Eudragit® RS.
  • polymethacrylates Handbook of Pharmaceutical Excipients, 2nd Ed., The Pharmaceutical Press, London 1994
  • poly(ethyl acrylate, methyl methacrylate, trimethylammoniumethyl methacrylate chloride) which are marketed under the brand name Eudragit® RS.
  • the bioavailability adjuvant is preferably a fatty acid ester of polyoxyethylene, in particular those described under the name Polysorbate (Handbook of Pharmaceutical Excipients, 2nd Ed., The Pharmaceutical Press, London, 1994), in particular those marketed under the brand name Montanox®.
  • the lubricant consists of a pharmaceutically acceptable common lubricant used in the preparation of microgranules, in particular talc.
  • the plasticizer is a pharmaceutically acceptable common plasticizer used for the preparation of microgranules, in particular esters of citric, phthalic and sebacic acids, in particular aliphatic esters such as triethyl citrate, dibutyl sebacate or diethyl phthalate, and mixtures thereof.
  • a phthalic acid ester is used for each active layer and a mixture of esters of citric and sebacic acids is used for each SR layer.
  • the protective coating or intercalating layer consists of a methacrylic type polymer, a plasticizer, a lubricant and optionally a bioavailability adjuvant.
  • the bilayer microgranules according to the invention advantageously have the following final composition, the percentages being expressed on a dry weight basis for a total of 100%: neutral granular support 10-20% active layer: active principle 45-60% binder 0.5-2% surfactant 0.5-1% plasticizer 0.5-1% SR layer: coating agent 10-30% bioavailability adjuvant 0.05-0.15% plasticizer 2-10% lubricant 2-10%.
  • each active layer may be identical or different depending on the rate and the amount of active principle which it is desired to release over time.
  • the necessary adaptations depending on the aim to be achieved are within the capability of any person skilled in the art.
  • microgranules according to the invention are prepared according to the usual techniques for mounting the active principle onto the neutral granular support followed by coating with the SR layer, the operation being repeated for the bilayer microgranules.
  • the active principle is mounted by discontinuous spraying of an aqueous-alcoholic solution containing the binder, the surfactant and optionally the plasticizer, in alternance with sequences of dusting of the active principle and sequences of leaving to stand.
  • Coating with each SR layer is then carried out by spraying an aqueous suspension containing the coating agent and the usual additives.
  • the SR microgranules thus obtained are then screened and dried.
  • the mounting excipients are weighed out in the following proportions: PVP K 17* (povidone) 50% of the total DV Sodium lauryl sulphate 25% of the total DV Diethyl phthalate 25% of the total DV Purified water 50% of the total S 95% ethyl alcohol 50% of the total S
  • the support grains (sugar spheres) are placed in a rotating coating turbomixer.
  • the active principle (hydrochloride) is mounted on the support grains by discontinuous spraying of the mounting suspension obtained above, in alternance with sequences of dusting of the active principle and sequences of leaving to stand. The dusting operation is repeated until the desired active principle content is obtained.
  • the microgranules obtained are screened and are then dried.
  • the purified water is poured into a stainless steel beaker and the Montanox 80 DF, the triethyl citrate and then the dibutyl sebacate are introduced portionwise with stirring. Stirring is continued until the solution is homogeneous, and the talc is then introduced portion-wise with stirring. Lastly, the Eudragit RS 30 D is added with stirring being continued until the suspension is homogeneous and then throughout the coating phase.
  • microgranules obtained above are placed in a rotating coating turbomixer and they are then coated by continuous spraying of the solution obtained above.
  • the mass of coated microgranules obtained is screened and they are then dried in a rotating turbomixer at room temperature, or by blowing with cold air if the room temperature is above 24° C.
  • the SR microgranules obtained are lubricated by adding talc during the mixing phase.
  • Microgranules 5 are obtained by a second coating of 400 g of microgranules 2 with the suspension of Example 1.1.
  • Microgranules 6 are obtained by a second coating of 500 g of microgranules 2 with the suspension of Example 1.1.
  • Microgranules 7 consist of a mixture of microgranules 5 and 6, lubricated with 0.5% talc.
  • Microgranules 8 are obtained by a second coating of 400 g of microgranules 2 with the suspension of Example 1.1.
  • Microgranules 9 consist of a mixture of microgranules 5 and 8, lubricated with 0.5% talc.
  • the Cardizem® CD was administered on an empty stomach (reference).
  • the Diltiazem CD was administered on an empty stomach (“test-fast”).
  • the Diltiazem CD was administered with simultaneous administration of a standardized meal, the American “breakfast” (“test-fed”).
  • the solution is prepared in a stainless steel container,
  • Neutral 30 support grains are placed in a rotating coating turbomixer
  • the active principle is mounted on the Neutral 30 grains by discontinuous spraying of the suspension described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand,
  • the mass of microgranules obtained is screened through a grille with a mesh size ranging from 0.85 to 1.18 mm,
  • microgranules are then dried in the rotating turbomixer
  • the suspension is prepared in a stainless steel container into which the Aquacoat ECD 30 is introduced,
  • microgranules to be coated are placed in a coating turbomixer,
  • microgranules are coated by continuous spraying of the suspension described above,
  • microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 2 h and then at room temperature for 7 h.
  • the active principle is mounted on the microgranules obtained after coating of the batch YED 006 ⁇ 1383, by discontinuous spraying of the suspension described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand,
  • microgranules are then dried in the rotating turbomixer at room temperature for 8 h.
  • the suspension is prepared in a stainless steel container into which the purified water is introduced,
  • microgranules to be coated are placed in a coating turbomixer,
  • microgranules are coated by continuous spraying of the suspension described above,
  • microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 1 h and then at 30° C. for 8 h.
  • the suspension is prepared in a stainless steel container into which the purified water is introduced,
  • microgranules to be coated (obtained from batch YED 005) are placed in a perforated turbomixer,
  • microgranules are coated at a temperature of 30° C. by continuous spraying of the suspension described above, in alternance with sequences of dusting with talc (amount identical to that placed in suspension),
  • the mass of microgranules obtained is screened through a grille with a mesh size ranging from 1.18 to 1.25 mm,
  • microgranules are then dried in a rotating turbomixer at a temperature of 30° C. for 1 h and then at 40° C. for 2 h,
  • the temperature is cooled to 30° C. before carrying out a second screening through a grille with a mesh size ranging from 1.18 to 1.25 mm,
  • microgranules are then returned to the rotating turbomixer at a temperature of 30° C., throughout the period between the completed coating phase and the following one,
  • the microgranules are screened through a grille with a mesh size of 0.60 mm,
  • the suspension is prepared in a stainless steel container into which the purified water is introduced,
  • Triethyl citrate is introduced portionwise into the stirred purified water
  • microgranules to be coated are placed in a coating turbomixer,
  • microgranules are premounted by continuous spraying of the suspension described above,
  • microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 1 h and then at room temperature for 7 h.
  • microgranules are then dried in the rotating turbomixer at room temperature for 8 h.
  • the suspension is prepared in a stainless steel container into which the purified water is introduced,
  • microgranules to be coated are placed in a coating turbomixer,
  • microgranules are coated by continuous spraying of the suspension described above,
  • microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 1 h and then at room temperature for 7 h.
  • microgranules to be coated are placed in a perforated turbomixer,
  • microgranules are coated at a temperature of 30° C. by continuous spraying of the suspension described above, in alternance with sequences of dusting with talc (amount identical to that placed in suspension),
  • the mass of microgranules obtained is screened through a grille with a mesh size ranging from 1.18 to 1.25 mm,
  • microgranules are then dried in a rotating turbomixer at a temperature of 30° C. for 1 h and then at 40° C. for 2 h,
  • the temperature is returned to 30° C. before carrying out a second screening through a grille with a mesh size ranging from 1.18 to 1.25 mm,
  • microgranules are then returned to the rotating turbomixer at a temperature of 30° C., throughout the period between the completed coating phase and the following one,
  • the microgranules are screened through a grille with a mesh size of 0.60 mm,
  • microgranules to be coated are placed in a perforated turbomixer,
  • microgranules are coated by continuous spraying of the suspension described above,
  • the mass of microgranules obtained is screened through the grille with a mesh size ranging from 1.18 to 1.25 mm,
  • microgranules are then dried in a rotating turbomixer at a temperature of 30° C. for 1 h and then at 40° C. for 2 h,
  • the temperature is returned to 30° C. before carrying out a second screening through a grille with a mesh size ranging from 1.18 to 1.25 mm,
  • microgranules are then returned to the rotating turbomixer at a temperature of 30° C., throughout the period between the completed coating phase and the following one,
  • the microgranules are screened through a grille with a mesh size of 0.60 mm,
  • the suspension is prepared in a stainless steel container into which the purified water is introduced,
  • microgranules to be coated are placed in a perforated turbomixer,
  • microgranules are premounted at a tempertare of 30° C. by continuous spraying of the suspension described above,
  • microgranules are then dried in a rotating turbomixer at a temperature of 35° C. for 10 h.
  • the active principle is mounted on the microgranules obtained from the protective coating of batch YED 006 B ⁇ 1392.2, by discontinuous spraying of the suspension described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand,
  • microgranules are then dried in the rotating turbomixer at room temperature for 8 h.
  • microgranules to be coated are placed in a perforated turbomixer,
  • microgranules are coated by continuous spraying of the suspension described above,
  • the mass of microgranules obtained is screened through a grille with a mesh size ranging from 1.18 to 1.25 mm,
  • microgranules are then dried in a rotating turbomixer at a temperature of 30° C. for 1 h and then 40° C. for 2 h,
  • the temperature is returned to 30° C. before carrying out a second screening through a grille with a mesh size ranging from 1.18 to 1.25 mm,
  • microgranules are then returned to the rotating turbomixer at a temperature of 30° C., throughout the period between the completed coating phase and the following one,
  • the microgranules are screened through a grille with a mesh size of 0.60 mm,
  • Neutral 30 support grains are placed in a rotating coating turbomixer
  • the active principle is mounted on the Neutral 30 grains by discontinuous spraying of the solution described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand,
  • the mass of microgranules obtained is screened through a grille with a mesh size ranging from 0.71 to 1.00 mm,
  • microgranules are then dried in the rotating turbomixer at room temperature for 3 to 8 h.
  • the suspension is prepared in a stainless steel container into which the purified water is introduced,
  • microgranules to be coated obtained from batch YED 001 are placed in a coating turbomixer,
  • microgranules are then dried in a rotating turbomixer at room temperature, throughout the period between the completed coating phase and the following one,
  • the mixture is made such that the amount of active principle provided by batch YED 001 A1 is equal to 40% of the total amount of active principle in the mixture. The remaining 60% are provided by batch YED 001 B1.
  • Neutral 30 support grains are placed in a rotating coating turbomixer
  • the active principle is mounted on the Neutral 30 grains by discontinuous spraying of the suspension described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand,
  • microgranules are then dried in the rotating turbomixer.
  • the suspension is prepared in a stainless steel container into which the purified water is introduced,
  • microgranules to be coated (obtained from batches YED 004 and YED 005) are placed in a perforated turbomixer,
  • microgranules are coated at a temperature of 30° C. by continuous spraying of the suspension described above,
  • the mass of microgranules obtained is screened through a grille with a mesh size ranging from 1.18 to 1.25 mm,
  • microgranules are then dried in a rotating turbomixer at a temperature of 30° C. for 1 h and then at 40° C. for 2 h,
  • the temperature is returned to 30° C. before carrying out a second screening through a grille with a mesh size ranging from 1.18 to 1.25 mm,
  • microgranules are then returned to the rotating turbomixer at a temperature of 30° C., throughout the period between the completed coating phase and the following one,
  • the microgranules are screened through a grille with a mesh size of 0.60 mm,
  • the mixture is made such that the amount of active principle provided by batch YED 004A is equal to 40% of the total amount of active principle in the mixture. The remaining 60% are provided by batch YED 005B.
  • microgranules to be coated are placed in a coating turbomixer,
  • microgranules are coated by continuous spraying of the suspension described above,
  • microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 2 h.
  • microgranules to be premounted are placed in a coating turbomixer
  • microgranules are premounted at a temperature of 30° C. by continuous spraying of the suspension described above,
  • microgranules are then dried in a rotating turbomixer at a temperature of 35° C. for 2 h.
  • the active principle is mounted on microgranules obtained from the protective coating of batch YED 005 ⁇ 1406, by discontinuous spraying of the suspension described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand,
  • microgranules are then dried in the rotating turbomixer at room temperature for 12 h.
  • microgranules to be coated are placed in a coating turbomixer,
  • microgranules are coated by continuous spraying of the suspension described above,
  • microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 1 h and then at room temperature for 7 h.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Novel forms of sustained-release microgranules (LP) containing diltiazem are disclosed. The microgranules consist of a neutral granular carrier coated with an active layer including diltiazem or a pharmaceutically acceptable salt thereof as the active principle, a surfactant and a binder, and an outer layer providing sustained release of the active principle (layer LP).

Description

  • The present invention relates to novel forms of sustained-release (SR) microgranules containing Diltiazem as active principle. [0001]
  • Diltiazem is a calcium-antagonist benzothiazepine derivative which is useful for the treatment of arterial hypertension. It may be administered in various forms: tablets, injectable solutions or gelatin capsules containing sustained-release granules. The latter have the advantage of allowing the administration to be taken as a single dose required for daily treatment. [0002]
  • Various forms of Diltiazem SR microgranules have been described in the prior art, the most advantageous being that described in patent application EP-A-0,149,920, comprising a core combining Diltiazem with a water-soluble organic acid, in particular fumaric acid. The reason for this is that Diltiazem, or its pharmaceutically acceptable salts, are sparingly soluble at neutral or basic pH, and the presence of a water-soluble organic acid has proven to be particularly important, making it possible to create a buffered acidic microenvironment, promoting both the dilution and the absorption of the Diltiazem in areas of the digestive tract where the pH is too high. It has, nevertheless, been observed that for these SR forms, the solubilization and absorption of Diltiazem were dependent on the absorption of food, and are different when uptake of the microgranules is carried out on an empty stomach or during meals. [0003]
  • Organic-acid-free SR microgranules have been described in patent application EP-A-0,613,370. The core of the microgranules consists here of a neutral grain coated with a succession of layers of a water-soluble polymer, on the one hand, and of Diltiazem on the other hand. [0004]
  • For these various forms, the sustained release of the active principle is ensured by one or more layers coating the core of the microgranules, generally combining two types of film-forming polymer material, one being water-insoluble and the other water-soluble. [0005]
  • The present invention relates to a novel form of SR microgranules containing Diltiazem, or a pharmaceutically acceptable salt thereof, which is free of water-soluble organic acid, making it possible to obtain solubilization and absorption of the active principle which are at least equivalent to those obtained in the presence of an acid. In addition, the present invention relates to a simple novel form of SR microgranules containing Diltiazem, which is easy to prepare. [0006]
  • The microgranules according to the invention comprise a neutral granular support coated with an active layer comprising Diltiazem or a pharmaceutically acceptable salt thereof, a surfactant and a binder, and a layer which ensures sustained release of the active principle (referred to hereinbelow as the SR layer). [0007]
  • More particularly, the microgranules in accordance with the present invention may be of several categories. [0008]
  • The first category is represented by microgranules whose SR layer ensures slow sustained release of the active principle. [0009]
  • The second category is represented by microgranules whose SR layer ensures rapid sustained release of the active principle. [0010]
  • The difference between these two categories of monolayer microgranules lies essentially in the thickness of the coating agent contained in the SR layer. Indeed, the thicker this SR layer is, the slower will be the diffusion of the active principle. [0011]
  • The dissolution profile of each of these two types of microgranule is determined in vitro using water as dissolution medium, and gives the following specifications: [0012]
    Preferred
    Hours Dissolution Dissolution
    Rapid microgranules:
     2 h 0-45% ≦30%
     6 h ≧50% ≧65%
    Slow microgranules:
    12 h 0-60% ≦30%
    20 h ≧50% ≧45%
    Mixture:
     1 h ≦15% ≦15%
     6 h ≦55% 25≧55%
    10 h 30-70% 30-60%
    16 h 30-85% 55-85%
    22 h — ≧80%
  • The present invention also relates to a third category of microgranules resulting from the coating of the SR layer which ensures slow sustained release of the active principle, that is to say of the SR layer of microgranules of the first category above, from another active layer comprising: [0013]
  • Diltiazem or a pharmaceutically acceptable salt thereof as active principle, [0014]
  • a surfactant, and [0015]
  • a binder, [0016]
  • itself coated with an external layer which ensures rapid sustained release of the active principle contained in this active layer. [0017]
  • In other words, these so-called “bilayer” microgranules consist, from the centre to the periphery, of a neutral granular support, of a first active layer, of an SR layer ensuring slow sustained release of the active principle contained in the first active layer, of a second active layer and of an SR layer ensuring rapid sustained release of the active principle contained in the second active layer. [0018]
  • It is understood that for the so-called “bilayer” microgranules, only the specifications described above and corresponding to the slow and mixed microgranules can be applied. [0019]
  • Advantageously, a so-called protective coating or intercalating layer is applied to the microgranule between the SR layer ensuring slow sustained release of the active principle and the second layer of active principle. [0020]
  • Indeed, it has been shown that during application of the second layer of Diltiazem, and/or during dissolution of the microgranules, interactions are established between the Diltiazem and the SR layer located between the two active layers, thereby leading to the modification of sustained release of the Diltiazem contained in the first active layer. This intercalating layer acts as it were as insulation between the two layers concerned, protecting them from each other. Another means of obtaining the same result would consist in using for the SR layer in question a coating agent which does not interact with the Diltiazem. [0021]
  • The neutral granular support consists of any pharmaceutically acceptable neutral granular support, with an average diameter of between 0.4 and 0.9 mm, preferably 0.4 and 0.6 mm. These are preferably grains consisting of sucrose and starch in a weight ratio in the region of 75/25, such as those described under the name “Sugar Spheres” (Handbook of Pharmaceutical Excipients, 2nd Ed., The Pharmaceutical Press, London, 1994). [0022]
  • The hydrochloride is preferably among the pharmaceutically acceptable salts of Diltiazem. [0023]
  • The surfactant may be an anionic, nonionic, cationic or amphoteric surfactant. It is preferably an anionic surfactant. Among the anionic surfactants are alkali metal (C[0024] 10-C20)alkyl sulphates, preferably sodium lauryl sulphate, alkali metal (C10-C20)alkyl sulphonates or alkali metal (C10-C20)alkyl benzenesulphonates. The term alkali metal is preferably understood to refer to sodium or potassium.
  • The binder consists of any pharmaceutically acceptable binder which is useful for coating neutral granular supports, in particular pharmaceutically acceptable polymers such as the polyvinylpyrrolidones described under the name povidone (Handbook of Pharmaceutical Excipients, 2nd Ed., The Pharmaceutical Press, London, 1994), or hydroxypropyl methyl celluloses (HPMC), polyethylene glycols (PEG), etc. [0025]
  • The active layer comprising the Diltiazem may also comprise other common additives, such as a plasticizer. [0026]
  • In general, the active principle/neutral granular support weight ratio is in the region of 4/1. The term active principle is understood to refer to Diltiazem or the pharmaceutically acceptable salts thereof. [0027]
  • The active principle/surfactant weight ratio is advantageously between 99/1 and 95/5, preferably about 98/2. [0028]
  • The active principle/binder weight ratio is itself between 99/1 and 90/10, preferably in the region of 97/3. [0029]
  • The monolayer microgranules according to the invention preferably comprise the following components for the support and the active layer, the percentages being given on a weight basis for a total of 100: [0030]
    neutral granular support 20-25%
    active principle 70-75%
    surfactant 0.5-5%  
    binder 0.5-10% 
    plasticizer  0-5%.
  • The bilayer microgranules according to the invention preferably comprise the following components for the support and the active layers, the percentages being given on a weight basis for a total of 100: [0031]
    neutral granular support 10-20%
    active principle 75-85%
    surfactant 0.5-5%  
    binder 0.5-10% 
    plasticizer 0.5-5%. 
  • Each SR layer consists of a coating agent which ensures the sustained release, optionally combined with one or more common additives, in particular a bioavailability adjuvant and/or a plasticizer and/or a lubricant. [0032]
  • The coating agent ensuring the sustained release is preferably a water-insoluble film-forming polymer, such as polymethacrylates (Handbook of Pharmaceutical Excipients, 2nd Ed., The Pharmaceutical Press, London 1994), in particular poly(ethyl acrylate, methyl methacrylate, trimethylammoniumethyl methacrylate chloride), which are marketed under the brand name Eudragit® RS. [0033]
  • The bioavailability adjuvant is preferably a fatty acid ester of polyoxyethylene, in particular those described under the name Polysorbate (Handbook of Pharmaceutical Excipients, 2nd Ed., The Pharmaceutical Press, London, 1994), in particular those marketed under the brand name Montanox®. [0034]
  • The lubricant consists of a pharmaceutically acceptable common lubricant used in the preparation of microgranules, in particular talc. [0035]
  • The plasticizer is a pharmaceutically acceptable common plasticizer used for the preparation of microgranules, in particular esters of citric, phthalic and sebacic acids, in particular aliphatic esters such as triethyl citrate, dibutyl sebacate or diethyl phthalate, and mixtures thereof. [0036]
  • Preferably, a phthalic acid ester is used for each active layer and a mixture of esters of citric and sebacic acids is used for each SR layer. [0037]
  • When it is present, the protective coating or intercalating layer consists of a methacrylic type polymer, a plasticizer, a lubricant and optionally a bioavailability adjuvant. [0038]
  • The monolayer microgranules according to the invention advantageously have the following final composition, the percentages being expressed on a weight basis for a total of 100%: [0039]
    neutral granular support 10-20%
    active layer:
    active principle 45-65%
    binder 0.5-2%  
    surfactant 0.5-1%  
    plasticizer 0.5-1%  
    SR layer:
    coating agent 10-30%
    bioavailability adjuvant 0.05-0.15%
    plasticizer  2-10%
    lubricant  2-10%.
  • The bilayer microgranules according to the invention advantageously have the following final composition, the percentages being expressed on a dry weight basis for a total of 100%: [0040]
    neutral granular support 10-20%
    active layer:
    active principle 45-60%
    binder 0.5-2%  
    surfactant 0.5-1%  
    plasticizer 0.5-1%  
    SR layer:
    coating agent 10-30%
    bioavailability adjuvant 0.05-0.15%
    plasticizer  2-10%
    lubricant  2-10%.
  • The active principle content of each active layer may be identical or different depending on the rate and the amount of active principle which it is desired to release over time. The necessary adaptations depending on the aim to be achieved are within the capability of any person skilled in the art. [0041]
  • The microgranules according to the invention are prepared according to the usual techniques for mounting the active principle onto the neutral granular support followed by coating with the SR layer, the operation being repeated for the bilayer microgranules. [0042]
  • The active principle is mounted by discontinuous spraying of an aqueous-alcoholic solution containing the binder, the surfactant and optionally the plasticizer, in alternance with sequences of dusting of the active principle and sequences of leaving to stand. [0043]
  • The Diltiazem microgranules thus obtained are then screened and dried. [0044]
  • Coating with each SR layer is then carried out by spraying an aqueous suspension containing the coating agent and the usual additives. The SR microgranules thus obtained are then screened and dried. [0045]
  • This operation of coating with each SR layer is repeated as many times as required to obtain the desired release kinetics. [0046]
  • Other characteristics of the microgranules according to the invention will become apparent on reading the examples which follow in which rotating turbomixers are preferably used, it also being possible to use any other coating machine, in particular one with a fluidized bed of the Glatt or Niro type, with the usual modifications known to those skilled in the art.[0047]
    • EXAMPLE 1 Preparation of Microgranules
  • 1.1 Preparation of the Mounting Solution [0048]
  • The mounting excipients are weighed out in the following proportions: [0049]
    PVP K 17* (povidone) 50% of the total DV
    Sodium lauryl sulphate 25% of the total DV
    Diethyl phthalate 25% of the total DV
    Purified water 50% of the total S
    95% ethyl alcohol 50% of the total S
  • The 95% ethyl alcohol is poured into a first stainless steel mixer and the PVP K 17 is then introduced portionwise with stirring. Stirring is continued until the solution is homogeneous. An alcoholic 15% PVP K 17 solution is obtained. [0050]
  • The purified water is poured into a second stainless steel mixer and the sodium lauryl sulphate is then introduced portionwise with stirring. Stirring is continued until the solution is homogeneous. An aqueous 7.5% sodium lauryl sulphate solution is obtained. [0051]
  • The above two solutions are then mixed together and the diethyl phthalate is added with stirring. [0052]
  • 1.2 Mounting of the Diltiazem [0053]
  • The support grains (sugar spheres) are placed in a rotating coating turbomixer. The active principle (hydrochloride) is mounted on the support grains by discontinuous spraying of the mounting suspension obtained above, in alternance with sequences of dusting of the active principle and sequences of leaving to stand. The dusting operation is repeated until the desired active principle content is obtained. The microgranules obtained are screened and are then dried. [0054]
  • Immediate-release microgranules of the following composition are obtained, the percentages being given on a weight basis: [0055]
    Diltiazem 73.05%
    support grains 22.55%
    PVP K 17 2.20%
    sodium lauryl sulphate 1.10%
    diethyl phthalate 1.10%
  • for a Diltiazem (hydrochloride) content of 735.75 mg/g of microgranules. [0056]
  • 1.3 Preparation of the Coating Solution [0057]
  • The following coating excipients are weighed out in the proportions indicated: [0058]
    Eudragit RS 30 D* DV* = 30.0% of the mass of Eudragit weighed out
    Dibutyl sebacate DV = 4.0% of the DV of Eudragit
    Montanox
    80 DF** DV = 0.4% of the DV of Eudragit
    Talc DV = 20.0% of the DV of Eudragit
    Triethyl citrate DV = 16.0% of the DV of Eudragit
    Purified water S° = 50.0% of the mass of Eudragit weighed out
  • The purified water is poured into a stainless steel beaker and the [0059] Montanox 80 DF, the triethyl citrate and then the dibutyl sebacate are introduced portionwise with stirring. Stirring is continued until the solution is homogeneous, and the talc is then introduced portion-wise with stirring. Lastly, the Eudragit RS 30 D is added with stirring being continued until the suspension is homogeneous and then throughout the coating phase.
  • 1.4 Coating of Microgranules [0060]
  • The microgranules obtained above are placed in a rotating coating turbomixer and they are then coated by continuous spraying of the solution obtained above. The mass of coated microgranules obtained is screened and they are then dried in a rotating turbomixer at room temperature, or by blowing with cold air if the room temperature is above 24° C. [0061]
  • This operational sequence is repeated as many times as required to obtain the desired kinetics. [0062]
  • Lastly, the SR microgranules obtained are lubricated by adding talc during the mixing phase. [0063]
    • EXAMPLE 2
  • By carrying out the process described in Example 1, varying the amount of Eudragit RS 30 D and of excipients, microgranules with the compositions described in Table I below are obtained. [0064]
    TABLE I
    % 1 2 3 4 5 6 7 8 9
    AP 55.56 62.17 51.92 55.81 61.49 45.1 50.37 50.50 54.12
    N 30 17.08 19.19 16.03 17.23 18.98 13.92 15.55 15.59 16.71
    PVP 1.86 1.87 1.56 1.98 1.85 1.36 1.52 1.52 1.63
    LAS 0.93 0.94 0.78 0.84 0.93 0.68 0.76 0.76 0.81
    DP 0.93 0.94 0.78 0.84 0.93 0.68 0.76 0.76 0.81
    E RS 16.83 10.59 20.60 16.45 11.27 27.19 21.72 21.98 18.10
    D S 2.73 0.42 0.83 0.66 0.44 1.12 0.88 0.88 0.72
    M 80 0.07 0.05 0.08 0.07 0.05 0.11 0.09 0.09 0.08
    Talc 2.85 2.13 4.12 3.79 2.25 5.47 4.86 4.39 4.11
    TC 1.15 1.71 3.31 2.64 1.81 4.37 3.49 3.53 2.91
    Total 100%
    Ng/g 555.63 599.55 504.51 516.05 602.03 452.62 497.29 482.36 536.31
  • Microgranules 4 consist of a mixture of microgranules 2 and 3, lubricated with 0.5% talc (%=weight of talc/weight of microgranules to be lubricated). [0065]
  • Microgranules 5 are obtained by a second coating of 400 g of microgranules 2 with the suspension of Example 1.1. [0066]
  • [0067] Microgranules 6 are obtained by a second coating of 500 g of microgranules 2 with the suspension of Example 1.1.
  • Microgranules 7 consist of a mixture of [0068] microgranules 5 and 6, lubricated with 0.5% talc.
  • Microgranules 8 are obtained by a second coating of 400 g of microgranules 2 with the suspension of Example 1.1. [0069]
  • Microgranules 9 consist of a mixture of microgranules 5 and 8, lubricated with 0.5% talc. [0070]
    • EXAMPLE 3 Dissolution Kinetics
  • The above microgranules are subjected to a study of the kinetics of dissolution in water over 24 hours. The results obtained are summarized in Table II below, expressed as a percentage of active principle in solution relative to the total active principle. [0071]
    TABLE II
    t (h) 1 2 3 4 5 6 7 8 9
    2 2.2 12.7 0.8 4.9 3.1 1.2 2.1 1.1 1.7
    4 29.6 82.9 1.1 36.4 37.0 1.4 19.9 1.7 20.2
    6 — 94.1 1.4 41.1 85.7 1.9 38.0 1.8 36.5
    8 — 97.2 1.9 42.2 90.8 2.3 39.9 2.1 38.2
    10 — 98.8 3.8 43.6 92.8 2.6 40.9 2.5 39.0
    12 50.6 100 30.9 56.2 94.1 3.0 41.5 3.2 39.7
    14 63.3 — 74.8 82.8 94.9 3.4 42.0 18.7 45.5
    16 — — 88.9 92.0 95.4 4.4 43.6 63.7 68.3
    18 94.4 — 93.7 95.0 95.7 12.5 50.7 84.6 83.4
    20 — — 96.5 96.7 96.0 55.7 65.9 91.0 88.1
    22 — — — 97.7 96.1 85.2 80.7 94.4 90.3
    24 98.0 — — 98.7 — — 92.3 — 91.5
    • EXAMPLE 4 Bioequivalence with Cardizem® CD
  • The bioequivalence of gelatin capsules dosed with 300 mg of Diltiazem and containing the microgranules of composition 9 (Diltiazem CD) was compared in vivo with Cardizem® CD 300 mg marketed by the company Marion Merrell Dow Inc. in the United States. [0072]
  • The studies were carried out on three groups of 12 patients, by measuring the concentration of active principle in the plasma. [0073]
  • For the first group, the Cardizem® CD was administered on an empty stomach (reference). [0074]
  • For the second group, the Diltiazem CD was administered on an empty stomach (“test-fast”). [0075]
  • For the third group, the Diltiazem CD was administered with simultaneous administration of a standardized meal, the American “breakfast” (“test-fed”). [0076]
  • The average plasmatic concentration curves are reported in the appended FIG. 1. [0077]
  • This study unequivocally recognizes the bioequivalence of Diltiazem CD according to the invention with Cardizem® CD, independently of the simultaneous taking of food. [0078]
    • EXAMPLE 5 Preparation of Bilayer Microgranules
  • 5.1—Bilayer Microgranules Free of Premounting Solution (Batch YED 006×1383.1) [0079]
  • A) Mounting of the First Layer of Diltiazem, Production of Batch YED 006. [0080]
  • a) Preparation of the Mounting Solution [0081]
  • Proportions of the excipients used: [0082]
    PVP K 17 50% of the total DV*
    SODIUM LAURYL SULPHATE 25% of the total DV
    DIETHYL PHTHALATE 25% of the total DV
    PURIFIED WATER 50% of the total S°
    95% ETHYL ALCOHOL 50% of the total S
  • The solution is prepared in a stainless steel container, [0083]
  • The 95% ethyl alcohol and then the purified water are poured into the container and then stirred, [0084]
  • The PVP K 17 and then the lauryl sulphate are introduced successively and portionwise, [0085]
  • Stirring is continued until the PVP K 17 and the lauryl sulphate are completely dissolved, [0086]
  • The diethyl phthalate is then added and stirring is continued until the solution is homogeneous. [0087]
  • b) Mounting of the Diltiazem onto Neutral Support Grains [0088]
  • Neutral 30 support grains are placed in a rotating coating turbomixer, [0089]
  • The active principle is mounted on the Neutral 30 grains by discontinuous spraying of the suspension described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand, [0090]
  • The mass of microgranules obtained is screened through a grille with a mesh size ranging from 0.85 to 1.18 mm, [0091]
  • The microgranules are then dried in the rotating turbomixer [0092]
  • at room temperature and for 2 [0093] h 30 between two consecutive phases.
  • at 35° C. and for 4 to 6 h for the final mounting phase of each day. After drying, the turbomixer is left rotating for 4 h without any heat being applied. [0094]
  • The mass obtained is then lubricated with talc. [0095]
  • c) Formulation of the Microgranules After Mounting of the First Layer of Diltiazem [0096]
    Composition of the DV* Amount in %
    DILTIAZEM 74.17
    NEUTRAL 30 21.26
    PVP K 17 2.16
    SODIUM LAURYL SULPHATE 1.08
    DIETHYL PHTHALATE 1.08
    TALC 0.24
    Theoretical content 741.7
    mg/g
    Content obtained 735.9
    mg/g
  • B) Internal Coating of the Batch YED 006, Production of Batch YED 006×1383 [0097]
  • a) Preparation of the Coating Suspension [0098]
  • Portions of the excipients used: [0099]
    AQUACOAT ECD 30 DV* = 30.0% of the mass
    of Aquacoat weighed out
    DIBUTYL SEBACATE DV = 24.0% of the DV of
    Aquacoat
  • The suspension is prepared in a stainless steel container into which the [0100] Aquacoat ECD 30 is introduced,
  • The dibutyl sebacate is introduced portionwise into the stirred Aquacoat, [0101]
  • Stirring is continued until the suspension is homogeneous (about 15 minutes). [0102]
  • b) Internal Coating of the Diltiazem Microgranules [0103]
  • The microgranules to be coated (obtained from batch YED 006) are placed in a coating turbomixer, [0104]
  • The microgranules are coated by continuous spraying of the suspension described above, [0105]
  • The mass of microgranules obtained is screened through a grille with a mesh size of 1.25 mm, [0106]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 2 h and then at room temperature for 7 h. [0107]
  • c) Formulation of Batch YED 006×1383 After Internal Coating [0108]
    Composition of the DV* Amount in %
    DILTIAZEM 56.61%
    NEUTRAL
    30 16.22%
    PVP K 17 1.65%
    SODIUM LAURYL SULPHATE 0.83%
    DIETHYL PHTHALATE 0.83%
    AQUACOAT BCD
    30 19.10%
    DIBUTYL SEBACATE 5.59%
    TALC 0.18%
    Theoretical content 566.1 mg/g
  • C) Mounting of the Second Layer of Diltiazem on Batch YED 006×1383, Production of Batch YED 006×1383.1 [0109]
  • a) Preparation of the Mounting Solution [0110]
  • Refer to paragraph A)a). [0111]
  • b) Mounting of the Diltiazem [0112]
  • The active principle is mounted on the microgranules obtained after coating of the batch YED 006×1383, by discontinuous spraying of the suspension described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand, [0113]
  • The mass of microgranules obtained screened through a grille with a mesh size of 1.50 mm, [0114]
  • The microgranules are then dried in the rotating turbomixer at room temperature for 8 h. [0115]
  • c) Formulation of the Batch YED 006×1383.1 After Mounting of the Second Layer of Diltiazem [0116]
    Composition of the DV* Amount in %
    DILTIAZEM 67.14%
    NEUTRAL
    30 11.54%
    PVP 17 2.17%
    SODIUM LAURYL SULPHATE 1.09%
    DIETHYL PHTHALATE 1.09%
    AQUACOAT ECD
    30 13.59%
    DIBUTYL SEBACATE 3.26%
    TALC 0.13%
    Theoretical content 674.1 mg/g
  • D) Outer Coating of the Batch YED 006×1383.1 [0117]
  • a) Preparation of the Coating Suspension [0118]
  • Proportions of the excipients used: [0119]
    EUDRAGIT RS 30 D DV* = 30.0% of the mass
    of Eudragit weighed out
    DIBUTYL SEBACATE DV = 4.0% of the DV of
    Eudragit
    POLYSORBATE
    80 DV = 0.4% of the DV of
    Eudragit
    TRIETHYL CITRATE DV = 16.0% of the DV of
    Eudragit
    TALC DV = 10.0% of the DV of
    Eudragit
    PURIFIED WATER S° = 50.0% of the mass of
    Eudragit weighed out
  • The suspension is prepared in a stainless steel container into which the purified water is introduced, [0120]
  • The [0121] Polysorbate 80, the triethyl citrate and the dibutyl sebacate (USP) are successively introdced portionwise into the stirred purified water,
  • Stirring is continued until the solution is homogeneous (about 15 minutes), [0122]
  • The Eudragit RS 30 D is then added, [0123]
  • Stirring is continued until the mixture is homogeneous (about 15 minutes) and then throughout the coating. [0124]
  • b) Outer coating of the Diltiazem microgranules [0125]
  • The microgranules to be coated are placed in a coating turbomixer, [0126]
  • The microgranules are coated by continuous spraying of the suspension described above, [0127]
  • The mass of microgranules obtained is screened through a grille with a mesh size of 1.40 mm, [0128]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 1 h and then at 30° C. for 8 h. [0129]
  • c) Formulation of Batch YED 006×1383.1 After External Coating [0130]
    Composition of the DV* Amount in %
    DILTIAZEM 58.99%
    NEUTRAL
    30 10.14%
    PVP K 17 1.91%
    SODIUM LAURYL SULPHATE 0.95%
    DIETHYL PHTHALATE 0.95%
    EUDRAGIT RS 30 D 8.62%
    AQUACOAT ECD
    30 11.94%
    DIBUTYL SEBACATE 3.22%
    POLYSORBATE
    80 0.04%
    TALC 1.84%
    TRIETHYL CITRATE 1.40%
    Theoretical content 589.9 mg/g
  • E) Results of Dissolution After the Internal Coating, Mounting of the Second Layer of Diltiazem and the External Coating [0131]
    YED 006 × 1381.1
    YED 006 × 1383 Mounting of the second YED 006 × 1383.1
    Internal coating layer of Diltiazem External coating
     1 h 1.38% 38.87% 0.68%
     2 h 9.45% 42.38% 1.82%
     3 h 20.33% 51.98% 8.49%
     4 h 28.82% 58.82% 28.41%
     5 h 34.99% 63.15% 37.67%
     6 h 39.84% 66.26% 41.68%
     7 h 43.92% 68.66% 45.31%
     8 h 47.37% 70.64% 48.64%
     9 h 50.58% 72.23% 51.51%
    10 h 53.27% 73.75% 54.00%
    11 h 55.77% 74.92% 56.12%
    12 h 57.96% 76.21% 58.23%
    13 h 59.96% 77.27% 59.89%
    14 h 61.94% 78.18% 61.63%
    15 h 63.62% 78.97% 63.14%
    16 h 65.30% 79.80% 64.56%
    17 h 66.62% 80.56% 66.06%
    18 h 68.25% 81.32% 67.42%
    19 h 69.52% 82.15% 68.78%
    20 h 70.79% 82.88% 70.21%
    21 h 71.95% 83.36% 71.57%
    22 h 73.12% 72.85%
    23 h 74.13% 74.02%
    24 h 75.10% 75.19%
  • Percentages of Diltiazem dissolved at each hour of sampling Formulations of batch YED 006×1383.1 [0132]
  • percentages given on a weight basis for a total of 100 (excluding coating): [0133]
    YED 006 × 1383.1
    Mounting
    Active principle 80.87%
    Neutral support 13.90%
    Binder 2.61%
    Surfactant 1.31%
    Plasticizer 1.31%
  • percentage on a dry weight basis for a total of 100% (final composition): [0134]
    YED 006 × 1383.1
    Neutral support 10.14%
    Mounting
    Active principle 58.99%
    Binder 1.91%
    Surfactant 0.95%
    Plasticizer 0.95%
    Coating
    Coating agent 20.56%
    Bioavailability adjuvant 0.04%
    Plasticizer 4.62%
    Lubricant 1.84%
  • 5.2—Bilayer microgranules with protective coating solution [0135]
  • I—Batch YED 005B×1350 [0136]
  • A) Mounting of the First Layer of Diltiazem, Production of Batch YED 005 [0137]
  • a) Preparation of the Mounting Solution [0138]
  • Refer to paragraph 5.1 A) a). [0139]
  • b) Mounting of Diltiazem on Neutral Support Grains [0140]
  • Refer to paragraph 5.1 A) b). [0141]
  • c) Formulation of Batch YED 005 After Mounting [0142]
    Composition of the DV* Amount in %
    DILTIAZEM 74.65%
    NEUTRAL
    30 21.37%
    PVP K 17 1.99%
    SODIUM LAURYL SULPHATE 1.00%
    DIETHYL PHTHALATE 1.00%
    Theoretical content 746.50 mg/g
    Content obtained 711.00 mg/g
  • B) Internal Coating of Batch YED 005, Production of Batch YED 005 B [0143]
  • a) Preparation of the Coating Suspension [0144]
  • Proportions of the excipients used: [0145]
    EUDRAGIT RS 30 D DV* = 30.0% of the mass of
    Eudragit weighed out
    DIBUTYL SEBACATE DV = 4.0% of the DV of
    Eudragit
    POLYSORBATE
    80 DV = 0.4% of the DV of
    Eudragit
    TALC DV = 10.0% of the DV of
    Eudragit
    TRIETHYL CITRATE DV = 16.0% of the DV of
    Eudragit
    PURIFIED WATER S° = 50.0% of the mass of
    Eudragit weighed out
  • The suspension is prepared in a stainless steel container into which the purified water is introduced, [0146]
  • The [0147] Polysorbate 80, the triethyl citrate and the dibutyl sebacate (USP) are introduced successively and portionwise into the stirred purified water,
  • Stirring is continued until the solution is homogeneous (about 15 minutes), [0148]
  • The Eudragit RS 30 D is then added, [0149]
  • The talc is introduced portionwise into the suspension, [0150]
  • Stirring is continued until the mixture is homogeneous (about 15 minutes) and then throughout the coating, [0151]
  • An amount of talc equivalent to that placed in suspension will be prepared in order to be dusted onto the mass during the coating, [0152]
  • b) Internal Coating of the Diltiazem Microgranules [0153]
  • The microgranules to be coated (obtained from batch YED 005) are placed in a perforated turbomixer, [0154]
  • The microgranules are coated at a temperature of 30° C. by continuous spraying of the suspension described above, in alternance with sequences of dusting with talc (amount identical to that placed in suspension), [0155]
  • The mass of microgranules obtained is screened through a grille with a mesh size ranging from 1.18 to 1.25 mm, [0156]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 30° C. for 1 h and then at 40° C. for 2 h, [0157]
  • The temperature is cooled to 30° C. before carrying out a second screening through a grille with a mesh size ranging from 1.18 to 1.25 mm, [0158]
  • The microgranules are then returned to the rotating turbomixer at a temperature of 30° C., throughout the period between the completed coating phase and the following one, [0159]
  • This operation sequence is repeated until the desired kinetics are obtained, [0160]
  • After the coating step, the microgranules are screened through a grille with a mesh size of 0.60 mm, [0161]
  • They are then lubricated with an amount of talc equivalent to 0.75% of the coated mass obtained. [0162]
  • c) Formulation of Batch YED 005 B After Internal Coating [0163]
    Composition of the DV* Amount in %
    DILTIAZEM 53.20%
    NEUTRAL
    30 15.23%
    PVP K 17 1.42%
    SODIUM LAURYL SULPHATE 0.71%
    DIETHYL PHTHALATE 0.71%
    EUDRAGIT RS 30 D 19.96%
    DIBUTYL SEBACATE 0.80%
    POLYSORBATE
    80 0.08%
    TALC 4.70%
    TRIETHYL CITRATE 3.19%
    Theoretical content 532.0 mg/g
    Content found 537.3 mg/g
  • C) Premounting of Batch YED 005 B, Production of Batch YED 005 B×1350 [0164]
  • a) Preparation of the Premounting Suspension [0165]
  • Proportions of the excipients used: [0166]
    EUDRAGIT L 30 D DV* = 30.0% of the mass of
    Eudragit weighed out
    TALC DV = 10.0% of the DV of
    Eudragit
    TRIETHYL CITRATE DV = 10.0% of the DV of
    Eudragit
    PURIFIED WATER DV = 50.0% of the mass of
    Eudragit weighed out
  • The suspension is prepared in a stainless steel container into which the purified water is introduced, [0167]
  • Triethyl citrate is introduced portionwise into the stirred purified water, [0168]
  • Stirring is continued until the solution is homogeneous (about 15 minutes), [0169]
  • The Eudragit L 30 D is then added, [0170]
  • The talc is introduced portionwise into the suspension, [0171]
  • Stirring is continued until the mixture is homogeneous (about 15 minutes) and then throughout the premounting. [0172]
  • b) Premounting of the Diltiazem Microgranules [0173]
  • The microgranules to be coated (obtained from batch YED 005 B) are placed in a coating turbomixer, [0174]
  • The microgranules are premounted by continuous spraying of the suspension described above, [0175]
  • The mass of microgranules obtained is screened through a grille with a mesh size of 1.50 mm, [0176]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 1 h and then at room temperature for 7 h. [0177]
  • c) Formulation of Batch YED 005 B×1350 After Protective Coating [0178]
    Composition of the DV* Amount in %
    DILTIAZEM 50.19%
    NEUTRAL
    30 14.36%
    PVP K 17 1.34%
    SODIUM LAURYL SULPHATE 0.67%
    DIETHYL PHTHALATE 0.67%
    EUDRAGIT RS 30 D 18.83%
    EUDRAGIT L 30 D 4.72%
    DIBUTYL SEBACATE 0.75%
    POLYSORBATE
    80 0.08%
    TALC 4.91%
    TRIETHYL CITRATE 3.19%
    Theoretical content 501.9 mg/g
    Content found 521.0 mg/g
  • D) Mounting of the Second Layer of Diltiazem on Batch YED 005 B×1350 [0179]
  • a) Preparation of the Mounting Solution [0180]
  • Refer to paragraph 5.1 A) a) [0181]
  • b) Mounting of the Diltiazem [0182]
  • The active principle is mounted on microgranules obtained from the premounting, by discontinuous spraying of the suspension described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand, [0183]
  • The mass of microgranules obtained is screened through a grille with a mesh size of 1.50 mm, [0184]
  • The microgranules are then dried in the rotating turbomixer at room temperature for 8 h. [0185]
  • c) Formulation of Batch YED 005×1350 After Mounting of the Second Layer of Diltiazem [0186]
    Composition of the DV* Amount in %
    DILTIAZEM 61.40%
    NEUTRAL
    30 10.60%
    PVP K 17 1.91%
    SODIUM LAURYL SULPHATE 0.95%
    DIETHYL PHTHALATE 0.95%
    EUDRAGIT RS 30 D 13.90%
    EUDRAGIT L 30 D 3.48%
    DIBUTYL SEBACATE 0.56%
    POLYSORBATE
    80 0.06%
    TALC 3.62%
    TRIETHYL CITRATE 2.57%
    Theoretical content 614.0 mg/g
  • E) External Coating of Batch YED 005 B×1350 [0187]
  • a) Preparation of the Coating Suspension [0188]
  • Proportions of the excipients used: [0189]
    EUDRAGIT RS 30 D DV* = 30.0% of the mass of
    Eudragit weighed out
    DIBUTYL SEBACATE DV = 4.0% of the DV of
    Eudragit
    POLYSORBATE
    80 DV = 0.4% of the DV of
    Eudragit
    TRIETHYL CITRATE DV = 16.0% of the DV of
    Eudragit
    TALC DV = 10.0% of the DV of
    Eudragit
    PURIFIED WATER DV = 50.0% of the mass of
    Eudragit weighed out
  • The suspension is prepared in a stainless steel container into which the purified water is introduced, [0190]
  • The [0191] Polysorbate 80, the triethyl citrate and the dibutyl sebacate (USP) are successively introduced portionwise into the stirred purified water,
  • Stirring is continued until the solution is homogeneous (about 15 minutes), [0192]
  • The Eudragit RS 30 D is then added, [0193]
  • Stirring is continued until the mixture is homogeneous (about 15 minutes) and then throughout the coating. [0194]
  • b) External Coating of the Diltiazem Microgranules [0195]
  • The microgranules to be coated are placed in a coating turbomixer, [0196]
  • The microgranules are coated by continuous spraying of the suspension described above, [0197]
  • The mass of microgranules obtained is screened through a grille with a mesh size of 1.50 mm, [0198]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 1 h and then at room temperature for 7 h. [0199]
  • c) Formulation of Batch YED 005 B×1350 After External Coating [0200]
    Composition of the DV* Amount in %
    DILTIAZEM 53.28%
    NEUTRAL
    30 9.20%
    PVP K 17 1.65%
    SODIUM LAURYL SULPHATE 0.83%
    DIETHYL PHTHALATE 0.83%
    EUDRAGIT RS 30 D 21.48%
    EUDRAGIT L 30 D 3.02%
    DIBUTYL SEBACATE 0.86%
    POLYSORBATE
    80 0.08%
    TALC 5 .03%
    TRIETHYL CITRATE 3.74%
    Theoretical content 532.8 mg/g
  • F) Results of Dissolution after the Internal Coating, Mounting of the Second Layer of Diltiazem and the External Coating [0201]
    YED 005 B × 1350
    YED 005 B Mounting of the second YED 005 B × 1350
    Internal coating layer of Diltiazem External coating
     1 h 0.23% 13.11% 1.90%
     2 h 0.51% 34.61% 10.53%
     3 h 0.65% 36.33% 35.30%
     4 h 0.83% 37.55% 38.56%
     5 h 0.93% 38.78% 41.59%
     6 h 0.97% 40.03% 44.92%
     7 h 1.25% 41.29% 48.11%
     8 h 1.53% 42.63% 51.59%
     9 h 2.31% 44.12% 55.45%
    10 h 4.44% 45.82% 59.30%
    11 h 9.02% 47.93% 63.07%
    12 h 17.11% 50.71% 67.30%
    13 h 28.43% 54.39% 71.45%
    14 h 42.29% 58.89% 75.45%
    15 h 55.17% 63.93% 78.63%
    16 h 64.91% 69.10% 81.57%
    17 h 71.75% 74.04% 84.01%
    18 h 76.41% 78.45% 86.43%
    19 h 79.59% 82.02%
    20 h 81.65% 84.85%
    21 h 83.31% 86.97%
    22 h 84.69% 88.66%
    23 h 85.85% 89.94%
    24 h 86.81% 90.98%
  • G) Formulations of Batch YED 005 B×1350 [0202]
  • percentages given on a weight basis for a total of 100 (excluding coating): [0203]
    YED 005 B × 1350
    Mounting
    Active principle 80.99%
    Neutral support 13.98%
    Binder 2.52%
    Surfactant 1.26%
    Plasticizer 1.26%
  • percentage on a dry weight basis for a total of 100% (final composition): [0204]
    YED 005 B × 1350
    Neutral support 9.20%
    Mounting
    Active principle 53.28%
    Binder 1.65%
    Surfactant 0.83%
    Plasticizer 0.83%
    Coating
    Coating agent 24.50%
    Bioavailability adjuvant 0.08%
    Plasticizer 4.60%
    Lubricant 5.03%
  • II—Batch YED 006×1392.2 [0205]
  • A) Mounting of the First Layer of Diltiazem, Production of Batch YED 006 [0206]
  • a) Preparation of the Mounting Solution [0207]
  • Refer to paragraph 5.1 A) a). [0208]
  • b) Mounting of the Diltiazem on Neutral Support Grains [0209]
  • Refer to paragraph 5.1 A) b), [0210]
  • The mass obtained is then lubricated with talc. [0211]
  • c) Formulation of Batch YED 006 After Mounting of the First Layer of Diltiazem [0212]
  • Refer to paragraph 5.1 B) a). [0213]
  • B) Internal Coating of Batch YED 006, Production of Batch YED 006 B [0214]
  • a) Preparation of the Coating Suspension [0215]
  • Refer to paragraph 5.2 B) a). [0216]
  • b) Internal Coating of the Diltiazem Microgranules (First Step) [0217]
  • The microgranules to be coated (obtained from batch YED 006) are placed in a perforated turbomixer, [0218]
  • The microgranules are coated at a temperature of 30° C. by continuous spraying of the suspension described above, in alternance with sequences of dusting with talc (amount identical to that placed in suspension), [0219]
  • The mass of microgranules obtained is screened through a grille with a mesh size ranging from 1.18 to 1.25 mm, [0220]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 30° C. for 1 h and then at 40° C. for 2 h, [0221]
  • The temperature is returned to 30° C. before carrying out a second screening through a grille with a mesh size ranging from 1.18 to 1.25 mm, [0222]
  • The microgranules are then returned to the rotating turbomixer at a temperature of 30° C., throughout the period between the completed coating phase and the following one, [0223]
  • This operational sequence is repeated until the desired kinetics are obtained, [0224]
  • After the coating step, the microgranules are screened through a grille with a mesh size of 0.60 mm, [0225]
  • They are then lubricated with an amount of talc equivalent to 0.75% of the coated mass obtained. [0226]
  • c) Formulation of Batch YED 006 B After Internal Coating [0227]
    Composition of the DV* Amount in %
    DILTIAZEM 69.18%
    NEUTRAL
    30 19.83%
    PVP K 17 2.02%
    SODIUM LAURYL SULPHATE 1.01%
    DIETHYL PHTHALATE 1.01%
    EUDRAGIT RS 30 D 4.66%
    DIBUTYL SEBACATE 0.19%
    POLYSORBATE
    80 0.02%
    TALC 1.35%
    TRIETHYL CITRATE 0.75%
    Theoretical content 691.8 mg/g
  • C) Internal Coating of Batch YED 006 B, Production of Batch YED 006 B×1392 [0228]
  • a) Preparation of the Coating Suspension [0229]
  • Refer to paragraph 5.1 B) a). [0230]
  • b) Internal Coating of the Diltiazem Microgranules (Second Step) [0231]
  • The microgranules to be coated (obtained from batch YED 006 B) are placed in a perforated turbomixer, [0232]
  • The microgranules are coated by continuous spraying of the suspension described above, [0233]
  • The mass of microgranules obtained is screened through the grille with a mesh size ranging from 1.18 to 1.25 mm, [0234]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 30° C. for 1 h and then at 40° C. for 2 h, [0235]
  • The temperature is returned to 30° C. before carrying out a second screening through a grille with a mesh size ranging from 1.18 to 1.25 mm, [0236]
  • The microgranules are then returned to the rotating turbomixer at a temperature of 30° C., throughout the period between the completed coating phase and the following one, [0237]
  • This operational sequence is repeated until the desired kinetics are obtained, [0238]
  • After the coating step, the microgranules are screened through a grille with a mesh size of 0.60 mm, [0239]
  • c) Formulation of Batch YED 006 B×1392 After Internal Coating [0240]
    Composition of the DV* Amount in %
    DILTIAZEM 52.29%
    NEUTRAL
    30 14.99%
    PVP K 17 1.53%
    SODIUM LAURYL SULPHATE 0.76%
    DIETHYL PHTHALATE 0.76%
    EUDRAGIT RS 30 D 20.91%
    DIBUTYL SEBACATE 0.84%
    POLYSORBATE
    80 0.08%
    TALC 4.49%
    TRIETHYL CITRATE 3.35%
    Theoretical content 522.9 mg/g
  • D) Premounting of Batch YED 006 B×1392, Production of Batch YED 006 B×1392.2 [0241]
  • a) Preparation of the Premounting Suspension [0242]
  • Proportions of the excipients used: [0243]
    EUDRAGIT L 30 D DV* = 30.0% of the mass of
    Eudragit weighed out
    TRIETHYL CITRATE DV = 10.0% of the DV of
    Eudragit
    PURIFIED WATER DV = 20.0% of the mass of
    Eudragit weighed out
  • The suspension is prepared in a stainless steel container into which the purified water is introduced, [0244]
  • The triethyl citrate is introduced portionwise into the stirred purified water, [0245]
  • Stirring is continued until the solution is homogeneous (about 15 minutes), [0246]
  • The Eudragit L 30 D is then added, [0247]
  • Stirring is continued until the mixture is homogeneous (about 15 minutes) and then throughout the premounting. [0248]
  • b) Premounting of the Diltiazem Microgranules [0249]
  • The microgranules to be coated are placed in a perforated turbomixer, [0250]
  • The microgranules are premounted at a tempertare of 30° C. by continuous spraying of the suspension described above, [0251]
  • The mass of microgranules obtained is screened through a grille with a mesh size of 1.40 mm, [0252]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 35° C. for 10 h. [0253]
  • c) Formulation of Batch YED 006 B×1392.2 After Premounting [0254]
    Composition of the DV* Amount in %
    DILTIAZEM 50.19%
    NEUTRAL
    30 14.36%
    PVP K 17 1.34%
    SODIUM LAURYL SULPHATE 0.67%
    DIETHYL PHTHALATE 0.67%
    EUDRAGIT RS 30 D 18.83%
    EUDRAGIT L 30 D 4.72%
    DIBUTYL SEBACATE 0.75%
    POLYSORBATE
    80 0.08%
    TALC 4.91%
    TRIETHYL CITRATE 3.19%
    Theoretical content 501.9 mg/g
  • E) Mounting of the Second Layer of Diltiazem on Batch YED 006 B×1392.2 [0255]
  • a) Preparation of the Mounting Solution [0256]
  • Refer to paragraph 5.2 A) a). [0257]
  • b) Mounting of the Diltiazem [0258]
  • The active principle is mounted on the microgranules obtained from the protective coating of batch YED 006 B×1392.2, by discontinuous spraying of the suspension described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand, [0259]
  • The mass of microgranules obtained is screened through a grille with a mesh size of 1.50 mm, [0260]
  • The microgranules are then dried in the rotating turbomixer at room temperature for 8 h. [0261]
  • c) Formulation of Batch YED 006 B×13912.2 After Mounting of the Second Layer of Diltiazem [0262]
    Composition of the DV* Amount in %
    DILTIAZEM 58.75%
    NEUTRAL
    30 10.11%
    PVP K 17 1.85%
    SODIUM LAURYL SULPHATE 0.93%
    DIETHYL PHTHALATE 0.92%
    EUDRAGIT RS 30 D 14.11%
    EUDRAGIT L 30 D 6.75%
    DIBUTYL SEBACATE 0.56%
    POLYSORBATE
    80 0.06%
    TALC 3.03%
    TRIETHYL CITRATE 2.93%
    Theoretical content 587.5 mg/g
  • F) External Coating of Batch YED 006 B×1392.2 [0263]
  • a) Preparation of the Coating Suspension [0264]
  • Refer to paragraph 5.2 B) a). [0265]
  • b) External Coating of the Diltiazem Microgranules [0266]
  • The microgranules to be coated are placed in a perforated turbomixer, [0267]
  • The microgranules are coated by continuous spraying of the suspension described above, [0268]
  • The mass of microgranules obtained is screened through a grille with a mesh size ranging from 1.18 to 1.25 mm, [0269]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 30° C. for 1 h and then 40° C. for 2 h, [0270]
  • The temperature is returned to 30° C. before carrying out a second screening through a grille with a mesh size ranging from 1.18 to 1.25 mm, [0271]
  • The microgranules are then returned to the rotating turbomixer at a temperature of 30° C., throughout the period between the completed coating phase and the following one, [0272]
  • This operational sequence is repeated until the desired kinetics are obtained, [0273]
  • After the coating step, the microgranules are screened through a grille with a mesh size of 0.60 mm, [0274]
  • They are then lubricated with an amount of talc equivalent to 1.5% of the coated mass obtained. [0275]
  • c) Formulation of Batch YED 006 B×1392.2 After External Coating [0276]
    Composition of the DV* Amount in %
    DILTIAZEM 49.71%
    NEUTRAL
    30 8.56%
    PVP K 17 1.57%
    SODIUM LAURYL SULPHATE 0.78%
    DIETHYL PHTHALATE 0.78%
    EUDRAGIT RS 30 D 21.89%
    EUDRAGIT L 30 D 5.71%
    DIBUTYL SEBACATE 0.88%
    POLYSORBATE
    80 0.09%
    TALC 5.97%
    TRIETHYL CITRATE 4.08%
    Theoretical content 497.1 mg/g
  • G) Results of Dissolution after Internal Coating and External Coating (in Two Media) [0277]
    H2O medium H2O media pH 7
    YED 006 B × 1392 YED 006 B × 1392.2
    Internal coating External coating
     1 h 0.61% 1.08% 1.46%
     2 h 0.84% 3.37% 5.60%
     3 h 0.99% 12.73% 16.72%
     4 h 1.14% 25.42% 21.59%
     5 h 1.29% 31.93% 22.82%
     6 h 1.44% 34.07% 23.43%
     7 h 1.67% 35.09% 23.85%
     8 h 1.90% 35.78% 24.31%
     9 h 2.66% 36.47% 24.62%
    10 h 4.63% 37.02% 25.04%
    11 h 10.38% 37.42% 25.53%
    12 h 22.73% 37.96% 26.07%
    13 h 40.08% 38.41% 26.83%
    14 h 57.50% 38.93% 27.71%
    15 h 71.26% 39.39% 28.93%
    16 h 80.11% 39.79% 30.34%
    17 h 85.78% 40.17% 32.39%
    18 h 89.03% 40.62% 35.14%
    19 h 91.07% 41.22% 38.47%
    20 h 92.65% 41.77% 42.07%
    21 h 93.65% 42.38% 45.81%
    22 h 43.22% 49.47%
    23 h 43.84% 52.74%
    24 h 44.74% 55.79%
  • H) Formulations of Batch YED 006×1392.2 [0278]
  • percentages given on a weight basis for a total of 100 (excluding coating): [0279]
    YED 006 × 1392.2
    Mounting
    Active principle 80.96%
    Neutral support 13.93%
    Binder 2.55%
    Surfactant 1.28%
    Plasticizer 1.27%
  • percentage on a dry weight basis for a total of 100% (final composition): [0280]
    YED 006 × 1392.2
    Neutral support 8.56%
    Mounting
    Active principle 49.71%
    Binder 1.57%
    Surfactant 0.78%
    Plasticizer 0.78%
    Coating
    Coating agent 27.59%
    Bioavailability adjuvant 0.09%
    Plasticizer 4.96%
    Lubricant 5.97%
    • EXAMPLE 6 Preparation of Monolayer Microgranules
  • A) Mounting of the Diltiazem, Production of batch YED 001 [0281]
  • a) Preparation of the Mounting Solution [0282]
  • Proportions of the excipients used: [0283]
    PVP K 17 50% of the total DV*
    SODIUM LAURYL 25% of the total DV DV = 15% of the weight
    SULPHATE of the solution
    DIETHYL 25% of the total DV
    PHTHALATE
    PURIFIED WATER 50% of the total S° S = 85% of the weight
    of the solution
    95% ETHYL 50% of the total S
    ALCOHOL
  • The solution is prepared in a stainless steel container, [0284]
  • The 95% ethyl alcohol and then the purified water are poured into the container and then stirred, [0285]
  • The PVP K 17 and then the lauryl sulphate are successively introduced portionwise, [0286]
  • Stirring is continued until the PVP K 17 and the lauryl sulphate have completely dissolved, [0287]
  • The diethyl phthalate is then added and stirring is continued until the solution is homogeneous. [0288]
  • b) Mounting of the Diltiazem on the Neutral Support Grains [0289]
  • Neutral 30 support grains are placed in a rotating coating turbomixer, [0290]
  • The active principle is mounted on the Neutral 30 grains by discontinuous spraying of the solution described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand, [0291]
  • The mass of microgranules obtained is screened through a grille with a mesh size ranging from 0.71 to 1.00 mm, [0292]
  • The microgranules are then dried in the rotating turbomixer at room temperature for 3 to 8 h. [0293]
  • c) Formulation of Batch YED 001 After Mounting [0294]
    Composition of the DV* Amount in %
    DILTIAZEM 73.05%
    NEUTRAL
    30 22.55%
    PVP K 17 2.20%
    SODIUM LAURYL SULPHATE 1.10%
    DIETHYL PHTHALATE 1.10%
    Theoretical content 730.50 mg/g
    Content obtained 735.75 mg/g
  • B) Coating of Batch YED 001, Production of Batches YED 001 A1 and YED 001 B1 [0295]
  • After separation of the mass of microgranules obtained on mounting (proportions: 45%/55% w/w), the two masses are coated separately with different amounts of excipients. [0296]
  • a) Preparation of the Coating Suspension [0297]
  • Proportions of the excipients used: [0298]
    EUDRAGIT RS 30 D DV* = 30.0% of the mass of Eudra-
    git weighed out
    DIBUTYL SEBACATE DV = 4.0% of the DV of Eudragit
    Polysorbate
    80 DV = 0.4% of the DV of Eudragit
    TRIETHYL CITRATE DV = 16.0% of the DV of Eudragit
    TALC DV = 10.0% of the DV of Eudragit
    PURIFIED WATER S ° = 50.0% of the mass of Eudragit
    weighed out
  • The suspension is prepared in a stainless steel container into which the purified water is introduced, [0299]
  • The [0300] Polysorbate 80, the triethyl citrate and the dibutyl sebacate (USP) are successively introduced portionwise into the stirred purified water,
  • Stirring is continued until the suspension is homogeneous (about 15 minutes), [0301]
  • The Eudragit RS 30 D and the talc are then added, [0302]
  • Stirring is continued until the mixture is homogeneous (about 15 minutes) and then throughout the coating. [0303]
  • b) Coating of the Diltiazem Microgranules [0304]
  • The microgranules to be coated (obtained from batch YED 001) are placed in a coating turbomixer, [0305]
  • The microgranules are coated at a temperature of 30° C. by continuous spraying of the suspension described above, in alternance with sequences of dusting with talc (DV=20% of the DV of Eudragit), [0306]
  • The mass of microgranules obtained is screened through a grille with a mesh size ranging from 1.00 to 1.12 mm, [0307]
  • The microgranules are then dried in a rotating turbomixer at room temperature, throughout the period between the completed coating phase and the following one, [0308]
  • This operational sequence is repeated until the desired kinetics for batches A1 and B1 are obtained. [0309]
  • c) Formulation of Batches YED 001 A1 and YED 001 B1 After Coating, YED 001 M3 Mixture [0310]
  • After the coating steps, a fraction of the granules obtained from batch YED 001 A1 and a fraction of the granules obtained from batch YED 001 B1 are mixed together and lubricated with talc (DV of talc=0.50% of the total mass mixed), [0311]
  • The mixture is made such that the amount of active principle provided by batch YED 001 A1 is equal to 40% of the total amount of active principle in the mixture. The remaining 60% are provided by batch YED 001 B1. [0312]
    Batch Amount in %
    Composition of the DV* YET 001A1 YED 001B1 YED 001M3
    DILTIAZEM 61.5% 45.1% 50.4%
    NEUTRAL
    30 19.0% 13.9% 15.5%
    PVP K 17 1.9% 1.4% 1.5%
    SODIUM LAURYL SULPHATE 0.9% 0.7% 0.8%
    DIETHYL PHTHALATE 0.9% 0.7% 0.8%
    EUDRAGIT RS 30 D 11.3% 27.2% 21.7%
    DIBUTYL SEBACATE 0.4% 1.1% 0.9%
    POLYSORBATE
    80 0.1% 0.1% 0.1%
    TALC 2.3% 5.5% 4.9%
    TRIETHYL CITRATE 1.8% 4.4% 3.5%
    Theoretical content 615 mg/g 451 mg/g 504 mg/g
    Content found 602 mg/g 453 mg/g 497 mg/g
  • C) Results of Dissolution of Batches YED 001A1, YED 001B1, YED 001M3, 8175 (Gelatin Capsules of Batch YED 001M3 Containing a 300 mg Dose) [0313]
    YED 001 A1 YED 001B1 YED 001M3 8175 (YED 001M3)
     1 h  0.60%  0.75%  0.50%  1.01%
     2 h  3.06%  1.20%  2.10%  3.36%
     3 h 10.69%  1.27%  6.70% 12.37%
     4 h 37.01%  1.42% 19.90% 26.77%
     5 h 72.92%  1.71% 33.80% 37.05%
     6 h 85.68%  1.93% 38.00% 40.37%
     7 h 89.04%  2.15% 39.20% 41.49%
     8 h 90.77%  2.29% 39.90% 42.19%
     9 h 91.97%  2.43% 40.50% 42.69%
    10 h 92.79%  2.57% 40.90% 43.10%
    11 h 93.61%  2.72% 41.20% 43.62%
    12 h 49.14%  3.00% 41.50% 44.18%
    13 h 94.53%  3.21% 41.70% 44.72%
    14 h 94.90%  3.43% 42.00% 45.30%
    15 h 95.12%  3.78% 42.50% 46.06%
    16 h 95.35%  4.43% 43.60% 46.81%
    17 h 95.50%  6.24% 45.60% 47.91%
    18 h 95.65% 12.46% 50.70% 50.80%
    19 h 95.73% 31.04% 58.00% 57.72%
    20 h 95.95% 55.72% 65.90% 69.03%
    21 h 96.03% 75.14% 73.20% 81.44%
    22 h 96.10% 85.19% 80.70% 90.49%
    23 h 87.50% 95.46%
    24 h 92.30% 98.12%
  • D) Formulations of batch YED 001 M3 [0314]
  • percentages given on a weight basis for a total of 100 (excluding coating): [0315]
    YED 001 M3
    Mounting
    Active principle 73.05%
    Neutral support 22.55%
    Binder  2.20%
    Surfactant  1.10%
    Plasticizer  1.10%
  • percentage on a dry weight basis for a total of 100% (final composition): [0316]
    YED 001 M3
    Neutral support 15.55
    Mounting
    Active principle 50.37%
    Binder 1.52%
    Surfactant 0.76%
    Plasticizer 0.76%
    Coating
    Coating agent 21.72%
    Bioavailability adjuvant 0.09%
    Plasticizer 4.37%
    Lubricant 4.86%
    • EXAMPLE 7 Preparation of Monolayer Microgranules
  • A) Mounting of Diltiazem, Production of Batches YED 004 and YED 005 [0317]
  • a) Preparation of the Mounting Soultion [0318]
  • Proportions of the excipients used: [0319]
    PVP K 17 50% of the
    total DV*
    SODIUM LAURYL 25% of the DV = 20% of the
    SULPHATE total DV weight of the solution
    DIETHYL PHTHALATE 25% of the
    total DV
    PURIFIED WATER 50% of the S = 20% of the
    total S ° weight of the solution
    95% ETHYL ALCOHOL 50% of the
    total S
  • The solution is prepared in a stainless steel container, [0320]
  • The 95% ethyl alcohol and then the purified water are poured into the container and then stirred, [0321]
  • The PVP K 17 and then the lauryl sulphate are successively introduced portionwise, [0322]
  • Stirring is continued until the PVP K 17 and the lauryl sulphate have completely dissolved, [0323]
  • The diethyl phthalate is then added and stirring is continued until the solution is homogeneous. [0324]
  • b) Mounting of the Diltiazem on the Neutral Support Grains [0325]
  • Neutral 30 support grains are placed in a rotating coating turbomixer, [0326]
  • The active principle is mounted on the Neutral 30 grains by discontinuous spraying of the suspension described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand, [0327]
  • The mass of microgranules obtained is screened through a grille with a mesh size ranging from 0.85 to 1.18 mm, [0328]
  • The microgranules are then dried in the rotating turbomixer. [0329]
  • YED 004: at 35° C. for 12 to 14 h, [0330]
  • YED 005: [0331]
  • At room temperature for 2 [0332] h 30 between two consecutive phases.
  • At 35° C. for 4 to 6 h for the final mounting phase of each day. [0333]
  • After drying, the turbomixer is left rotating for 4 h without any heat being supplied. [0334]
  • c) Formulation of Batches YED 004 and YED 005 After Mounting [0335]
    BATCH YED 004 YED 005
    Composition of the DV* Amount in % Amount in %
    DILTIAZEM 73.94 74.65
    NEUTRAL 30 21.20 21.37
    PVP K 17 2.43 1.99
    SODIUM LAURYL SULPHATE 1.21 1.00
    DIETHYL PHTHALATE 1.21 1.00
    THEORETICAL CONTENT 739.4 mg/g 746.5 mg/g
    CONTENT OBTAINED 727.8 mg/g 711.0 mg/g
  • B) Coating of Batches YED 004 and YED 005, Production of Batches YED 004A and YED 005B [0336]
  • After separation of the masses of microgranules obtained on mounting (proportions: 40%/60% w/w), two of the masses YED 004A (40% of YED 004) and YED 005B (60% of YED 005) are coated separately with different amounts of excipients. [0337]
  • a) Preparation of the Coating Suspension [0338]
  • Proportions of the excipients used: [0339]
    EUDRAGIT RS 30 D DV* = 30.0% of the mass of Eudragit
    weighed out
    DIBUTYL SEBACATE DV = 4.0% of the DV of Eudragit
    Polysorbate
    80 DV = 0.4% of the DV of Eudragit
    TALC DV = 10.0% of the DV of Eudragit
    TRIETHYL CITRATE DV = 16.0% of the DV of Eudragit
    PURIFIED WATER S ° = 50.0% of the mass of
    Eudragit weighed out
  • The suspension is prepared in a stainless steel container into which the purified water is introduced, [0340]
  • The [0341] Polysorbate 80, the triethyl citrate and the dibutyl sebacate (USP) are successively introduced portionwise into the stirred purified water,
  • Stirring is continued until the suspension is homogeneous (about 15 minutes), [0342]
  • The Eudragit RS 30 D is then added, [0343]
  • The talc is introduced portionwise into the suspension, [0344]
  • Stirring is continued until the mixture is homogeneous (about 15 minutes) and then throughout the coating, [0345]
  • b) Coating of the Diltiazem Microgranules [0346]
  • The microgranules to be coated (obtained from batches YED 004 and YED 005) are placed in a perforated turbomixer, [0347]
  • The microgranules are coated at a temperature of 30° C. by continuous spraying of the suspension described above, [0348]
  • The mass of microgranules obtained is screened through a grille with a mesh size ranging from 1.18 to 1.25 mm, [0349]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 30° C. for 1 h and then at 40° C. for 2 h, [0350]
  • The temperature is returned to 30° C. before carrying out a second screening through a grille with a mesh size ranging from 1.18 to 1.25 mm, [0351]
  • The microgranules are then returned to the rotating turbomixer at a temperature of 30° C., throughout the period between the completed coating phase and the following one, [0352]
  • This operational sequence is repeated until the desired kinetics are obtained, [0353]
  • After the coating step, the microgranules are screened through a grille with a mesh size of 0.60 mm, [0354]
  • They are then lubricated with an amount of talc equivalent to 0.75% of the coated mass obtained. [0355]
  • c) Formulation of batches YED 004A and YED 005B after coating, YED 005M mixture [0356]
  • A fraction of the granules obtained from batch YED 004A and a fraction of the granules obtained from batch YED 005B are mixed together, [0357]
  • The mixture is made such that the amount of active principle provided by batch YED 004A is equal to 40% of the total amount of active principle in the mixture. The remaining 60% are provided by batch YED 005B. [0358]
    YED 004A YED 005B YED 005M
    BATCH Amount Amount Amount
    Composition of the DV* in % in % in %
    DILTIAZEM 65.37 53.20 57.43
    NEUTRAL 30 18.75 15.23 16.45
    PVP K 17 2.15 1.42 1.68
    SODIUM LAURYL SULPHATE 1.07 0.71 0.84
    DIETHYL PHTHALATE 1.07 0.71 0.84
    EUDRAGIT RS 30 D 7.74 19.96 15.67
    DIBUTYL SEBACATE 0.31 0.80 0.63
    POLYSORBATE 80 0.04 0.08 0.07
    TALC 2.27 4.70 3.91
    TRIETHYL CITRATE 1.24 3.19 2.51
    THEORETICAL CONTENT 654 mg/g 532 mg/g 574 mg/g
    CONTENT FOUND 656 mg/g 537 mg/g 540 mg/g
  • C) Results of Dissolution of Batches YED 004A, YED 005B, YED 005M, 8394 (Gelatin Capsules of Batch YED 005M Containing a 300 mg Dose) [0359]
    YED 004A YED 005B YED 005M 8394
     1 h 3.99 0.26 2.15 2.31
     2 h 11.32 0.56 6.25 6.85
     3 h 32.46 0.72 16.70 19.15
     4 h 65.74 0.92 30.03 33.44
     5 h 85.57 1.02 35.81 39.44
     6 h 92.79 1.07 37.60 41.49
     7 h 95.83 1.38 38.52 42.54
     8 h 97.58 1.69 39.18 43.24
     9 h 99.07 2.55 39.84 43.98
    10 h 100.21 4.90 40.61 44.83
    11 h 100.98 9.96 42.40 46.23
    12 h 101.80 18.90 45.62 48.74
    13 h 102.26 31.41 51.18 52.71
    14 h 102.77 46.73 58.46 58.53
    15 h 103.08 60.96 67.33 65.63
    16 h 103.23 71.72 75.60 73.50
    17 h 103.70 79.27 82.28 80.27
    18 h 103.69 84.42 87.18 85.46
    19 h 103.90 87.94 90.44 89.21
    20 h 103.90 90.21 92.66 97.88
    21 h 103.90 92.05 94.39 93.75
    22 h 103.95 93.58 95.67 95.15
    23 h 103.89 94.85 96.73 96.30
    24 h 103.94 95.92 97.70 97.29
  • D) Formulations of Batch YED 005 M [0360]
  • percentages given on a weight basis for a total of 100 (excluding coating): [0361]
    YED 005 M
    Mounting
    Active principle 74.37%
    Neutral support 21.30%
    Binder 2.17%
    Surfactant 1.08%
    Plasticizer 1.08%
  • percentage on a dry weight basis for a total of 100% (final composition): [0362]
    YED 005 M
    Neutral support 16.45%
    Mounting
    Active principle 57.43%
    Binder 1.68%
    Surfactant 0.84%
    Plasticizer 0.84%
    Coating
    Coating agent 15.67%
    Bioavailability adjuvant 0.07%
    Plasticizer 3.13%
    Lubricant 3.91%
    • EXAMPLE 8 Preparation of Bilayer Microgranules
  • A) Mounting of the First Layer of Diltiazem, Production of Batch YED 005 [0363]
  • Refer to paragraph A) of Example 8. [0364]
  • B) Internal Coating of Batch YED 005, Production of Batch YED 005×1406 [0365]
  • a) Preparation of the Coating Suspension [0366]
  • Refer to paragraph B) a) of Example 8. [0367]
  • b) Internal Coating of the Diltiazem Microgranules [0368]
  • The microgranules to be coated are placed in a coating turbomixer, [0369]
  • The microgranules are coated by continuous spraying of the suspension described above, [0370]
  • The mass of microgranules obtained is screened through a grille with a mesh size of 1.50 mm, [0371]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 2 h. [0372]
  • c) Formulation of Batch YED 005×1406 After Internal Coating [0373]
    Amount
    Composition of the DV* in %
    DILTIAZEM 58.12
    NEUTRAL 30 16.63
    PVP K 17 1.55
    SODIUM LAURYL SULPHATE 0.78
    DIETHYL PHTHALATE 0.78
    EUDRAGIT RS 30 D 15.61
    DIBUTYL SEBACATE 0.62
    POLYSORBATE 80 0.06
    TALC 3.35
    TRIETHYL CITRATE 2.50
    THEORETICAL CONTENT 581.2 mg/g
  • C) Premounting of Batch YED 005×1406 [0374]
  • a) Preparation of the Premounting Suspension [0375]
  • Refer to paragraph II D) a) of Example 5.2. [0376]
  • b) Premounting of the Diltiazem Microgranules [0377]
  • The microgranules to be premounted are placed in a coating turbomixer, [0378]
  • The microgranules are premounted at a temperature of 30° C. by continuous spraying of the suspension described above, [0379]
  • The mass of microgranules obtained is screened through a grille with a mesh size of 1.50 mm, [0380]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 35° C. for 2 h. [0381]
  • c) Formulation of Batch YED 005×1406 After Premounting [0382]
    Amount
    Composition of the DV* in %
    DILTIAZEM 52.36
    NEUTRAL 30 14.98
    PVP K 17 1.40
    SODIUM LAURYL SULPHATE 0.70
    DIETHYL PHTHALATE 0.70
    EUDRAGIT RS 30 D 14.06
    EUDRAGIT L 30 D 9.01
    DIBUTYL SEBACATE 0.56
    POLYSORBATE 80 0.06
    TALC 3.02
    TRIETHYL CITRATE 3.16
    THEORETICAL CONTENT 523.6 mg/g
  • D) Mounting of the Second Layer of Diltiazem on Batch YED 005×1406 [0383]
  • a) Preparation of the Mounting Solution [0384]
  • Refer to paragraph A) a) of Example 8. [0385]
  • b) Mounting of the Diltiazem [0386]
  • The active principle is mounted on microgranules obtained from the protective coating of batch YED 005×1406, by discontinuous spraying of the suspension described above, in alternance with sequences of dusting of the Diltiazem and sequences of leaving to stand, [0387]
  • The mass of microgranules obtained is screened through a grille with a mesh size of 1.60 to 1.80 mm, [0388]
  • The microgranules are then dried in the rotating turbomixer at room temperature for 12 h. [0389]
  • c) Formulation of Batch YED 005×1406 After Mounting of the Second Layer of Diltiazem [0390]
    Amount
    Composition of the DV* in %
    DILTIAZEM 62.58
    NEUTRAL 30 11.08
    PVP K 17 2.13
    SODIUM LAURYL SULPHATE 1.06
    DIETHYL PHTHALATE 1.06
    EUDRAGIT RS 30 D 10.40
    EUDRAGIT L 30 D 6.66
    DIBUTYL SEBACATE 0.41
    POLYSORBATE 80 0.04
    TALC 2.23
    TRIETHYL CITRATE 2.33
    THEORETICAL CONTENT 625.8 mg/g
  • E) External Coating of Batch YED 005×1406 [0391]
  • a) Preparation of the Coating Suspension [0392]
  • Refer to paragraph B) a) of Example 8. [0393]
  • b) External Coating of the Diltiazem Microgranules [0394]
  • The microgranules to be coated are placed in a coating turbomixer, [0395]
  • The microgranules are coated by continuous spraying of the suspension described above, [0396]
  • The mass of microgranules obtained is screened through a grille with a mesh size of 1.50 mm, [0397]
  • The microgranules are then dried in a rotating turbomixer at a temperature of 40° C. for 1 h and then at room temperature for 7 h. [0398]
  • c) Formulation of Batch YED 005×1406 After External Coating [0399]
    Amount
    Composition of the DV* in %
    DILTIAZEM 55.46
    NEUTRAL 30 9.82
    PVP K 17 1.88
    SODIUM LAURYL SULPHATE 0.94
    DIETHYL PHTHALATE 0.94
    EUDRAGIT RS 30 D 16.30
    EUDRAGIT L 30 D 5.91
    DIBUTYL SEBACATE 0.65
    POLYSORBATE 80 0.07
    TALC 4.82
    TRIETHYL CITRATE 3.20
    THEORETICAL CONTENT 554.6 mg/g
  • F) Results of Dissolution After Internal Coating and External Coating (in Two Media) [0400]
    F) Results of dissolution after internal coating and external coating (in two media)
    pH 7
    H2O YED 005 × 1406
    YED 005 × 1406 YED 005 × 1406 YED 005 × 1406 Mounting of the YED 005 × 1406
    Internal External YED 005 × 1406 second layer of External
    coating Premounting coating Premounting Diltiazem coating
    (in %) (in %) (in %) (in %) (in %) (in %)
     1 h 0.08 0.35 7.35 0.40 39.51 16.72
     2 h 0.35 0.46 32.78 0.66 39.67 31.36
     3 h 0.53 0.51 36.32 0.81 39.76 32.44
     4 h 0.70 0.55 37.09 1.01 39.85 32.61
     5 h 1.20 0.61 37.39 1.21 39.93 32.84
     6 h 2.53 0.66 37.76 1.61 40.15 33.13
     7 h 5.96 0.70 38.06 2.42 40.45 33.36
     8 h 15.30 0.81 38.17 6.81 40.77 33.93
     9 h 38.46 1.06 38.41 21.45 41.83 34.84
    10 h 67.09 1.91 38.72 39.58 44.51 36.50
    11 h 84.19 5.19 39.04 51.16 50.59 39.63
    12 h 91.67 13.24 39.63 57.65 62.44 44.44
    13 h 95.19 22.93 40.53 62.19 75.44 50.52
    14 h 97.22 30.22 41.72 65.61 83.95 56.66
    15 h 98.59 35.49 43.21 68.12 87.96 62.41
    16 h 99.99 35.96 44.99 70.28 89.97 67.04
    17 h 100.84 42.77 46.91 71.89 90.94 70.91
    18 h 101.59 45.36 49.49 73.18 91.69 74.04
     9 h 102.34 47.84 52.20 74.75 92.29 76.36
    20 h 102.89 50.05 55.51 75.80 92.95 78.34
    21 h 103.34 51.88 58.72 76.84 93.40 79.91
    22 h 103.81 53.78 62.01 77.69 93.78 81.11
    23 h 104.29 55.59 65.15 78.70 94.14 82.28
    24 h 104.69 57.19 68.06 79.50 94.37 83.04
    Percentage of Diltiazem dissolved at each hour of sampling
  • G) Formulations of Batch YED 005×1406 [0401]
  • percentages given on a weight basis for a total of 100 (excluding coating): [0402]
    YED 005 × 1406
    Mounting
    Active principle 80.32%
    Neutral support 14.22%
    Binder 2.73%
    Surfactant 1.36%
    Plasticizer 1.36%
  • percentage on a dry weight basis for a total of 100% (final composition): [0403]
    YED 005 × 1406
    Neutral support 9.82%
    Mounting
    Active principle 55.46%
    Binder 1.88%
    Surfactant 0.94%
    Plasticizer 0.94%
    Coating
    Coating agent 22.21%
    Bioavailability adjuvant 0.07%
    Plasticizer 3.85%
    Lubricant 4.82%

Claims (21)

1. Sustained-release (SR) microgranules containing Diltiazem, characterized in that they comprise:
a neutral granular support coated with an active layer comprising:
Diltiazem or a pharmaceutically acceptable salt thereof as active principle,
a surfactant, and
a binder,
and a layer which ensures sustained release of the active principle (SR layer).
2. Microgranules according to claim 1, characterized in that the SR layer ensures slow sustained release of the active principle.
3. Microgranules according to claim 1, characterized in that the SR layer ensures rapid sustained release of the active principle.
4. Microgranules according to claim 2, characterized in that the SR layer which ensures slow sustained release of the active principle is itself coated with another active layer comprising:
Diltiazem or a pharmaceutically acceptable salt thereof as active principle,
a surfactant, and
a binder,
itself coated with an external layer which ensures rapid sustained release of the active principle contained in this active layer.
5. Microgranules according to claim 4, characterized in that they also comprise an intercalating layer between the SR layer which ensures slow release of the active principle and the active layer coating this SR layer.
6. Microgranules according to one of claims 1 to 5, characterized in that the surfactant is an anionic, nonionic, cationic or amphoteric surfactant.
7. Microgranules according to claim 6, characterized in that the surfactant is an anionic surfactant chosen, in particular, from alkali metal (C10-C20)alkyl sulphates, preferably sodium lauryl sulphate, alkali metal (C10-C20)alkyl sulphonates or alkali metal (C10-C20)alkyl benzenesulphonates.
8. Microgranules according to one of claims 1 to 7, characterized in that the binder consists of any pharmaceutically acceptable binder which is useful for coating neutral granular supports, in particular pharmaceutically acceptable polymers such as polyvinylpyrrolidones.
9. Microgranules according to one of claims 1 to 8, characterized in that each active layer also comprises a plasticizer, preferably a phthalic acid ester.
10. Microgranules according to one of claims 1 to 9, characterized in that the active principle/surfactant weight ratio is between 99/1 and 95/5, preferably about 98/2.
11. Microgranules according to one of claims 1 to 10, characterized in that the active principle/binder weight ratio is between 99/1 and 90/10, preferably in the region of 97/3.
12. Microgranules according to one of claims 1 to 3, characterized in that they comprise the following components for the support and the active layer, the percentages being given on a weight basis for a total of 100:
neutral granular support 20-25% active principle 70-75% surfactant 0.5-5%   binder 0.5-10%  plasticizer 0-5%
13. Microgranules according to claim 4, characterized in that they comprise the following components for the support and the active layers, the percentages being given on a weight basis for a total of 100:
neutral granular support 10-20% active principle 75-85% surfactant 0.5-5%   binder 0.5-10%  plasticizer 0.5-5%  
14. Microgranules according to one of claims 1 to 13, characterized in that each SR layer consists of a coating agent which ensures sustained release, optionally combined with one or more common additives, in particular a bioavailability adjuvant and/or a plasticizer and/or a lubricant.
15. Microgranules according to claim 14, characterized in that the coating agent ensuring the sustained release is a water-insoluble film-forming polymer, such as polymethacrylates.
16. Microgranules according to either of claims 14 and 15, characterized in that the bioavailability adjuvant is preferably a fatty acid ester of polyoxyethylene, in particular those described under the name Polysorbate.
17. Microgranules according to one of claims 14 to 16, characterized in that the lubricant is talc.
18. Microgranules according to one of claims 14 to 17, characterized in that the plasticizer is a pharmaceutically acceptable common plasticizer used for the preparation of microgranules, in particular esters of citric, phthalic and sebacic acids, such as triethyl citrate, dibutyl sebacate or diethyl phthalate, and mixtures thereof.
19. Microgranules according to one of claims 1 to 3, characterized in that they have the following final composition, the percentages being expressed on a dry weight basis for a total of 100%:
neutral granular support 10-20% active layer: active principle 45-65% binder 0.5-2%   surfactant 0.5-1%   plasticizer 0.5-1%   SR layer: coating agent 10-30% bioavailability adjuvant 0.05-0.15% plasticizer  2-10% lubricant   2-10%.
20. Microgranules according to claim 4, characterized in that they have the following final composition, the percentages being expressed on a dry weight basis for a total of 100%:
neutral granular support  5-15% active layers: active principle 45-65% binder 0.5-2.5% surfactant 0.75-1.25% plasticizer 0.75-1.25% SR layers: coating agent 15-35% bioavailability adjuvant 0.02-0.15% plasticizer  2-10% lubricant  2-10%
21. Gelatin capsules comprising microgranules according to one of claims 1 to 20.
US09/998,911 1995-12-22 2001-12-03 Sustained-release microgranules containing diltiazem as active principle Expired - Lifetime US6660296B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/998,911 US6660296B2 (en) 1995-12-22 2001-12-03 Sustained-release microgranules containing diltiazem as active principle

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
FR9515361 1995-12-22
FR95/5361 1995-12-22
FR9515361A FR2742660B1 (en) 1995-12-22 1995-12-22 NOVEL FORMS OF EXTENDED RELEASE MICROGRANULES CONTAINING DILTIAZEM AS ACTIVE INGREDIENT
US09/091,646 US6228395B1 (en) 1995-12-22 1996-12-23 Sustained-release microgranules containing Diltiazem as the active principle
US75691301A 2001-01-10 2001-01-10
US09/998,911 US6660296B2 (en) 1995-12-22 2001-12-03 Sustained-release microgranules containing diltiazem as active principle

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US75691301A Continuation 1995-12-22 2001-01-10

Publications (2)

Publication Number Publication Date
US20020182253A1 true US20020182253A1 (en) 2002-12-05
US6660296B2 US6660296B2 (en) 2003-12-09

Family

ID=9485856

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/091,646 Expired - Fee Related US6228395B1 (en) 1995-12-22 1996-12-23 Sustained-release microgranules containing Diltiazem as the active principle
US09/757,628 Expired - Lifetime US6383516B1 (en) 1995-12-22 2001-01-11 Sustained-release microgranules containing diltiazem as active principle
US09/998,911 Expired - Lifetime US6660296B2 (en) 1995-12-22 2001-12-03 Sustained-release microgranules containing diltiazem as active principle

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/091,646 Expired - Fee Related US6228395B1 (en) 1995-12-22 1996-12-23 Sustained-release microgranules containing Diltiazem as the active principle
US09/757,628 Expired - Lifetime US6383516B1 (en) 1995-12-22 2001-01-11 Sustained-release microgranules containing diltiazem as active principle

Country Status (27)

Country Link
US (3) US6228395B1 (en)
EP (1) EP0868184B1 (en)
JP (1) JP2000506500A (en)
KR (1) KR100354054B1 (en)
CN (1) CN1145488C (en)
AR (1) AR004410A1 (en)
AT (1) ATE238798T1 (en)
AU (1) AU721949B2 (en)
BG (1) BG63770B1 (en)
BR (1) BR9612225A (en)
CA (1) CA2242224C (en)
DE (1) DE69627880T2 (en)
DK (1) DK0868184T3 (en)
EA (1) EA001721B1 (en)
EE (1) EE04045B1 (en)
ES (1) ES2198505T3 (en)
FR (1) FR2742660B1 (en)
GE (1) GEP20022629B (en)
HK (1) HK1018400A1 (en)
HU (1) HU224214B1 (en)
IL (1) IL125047A (en)
NO (1) NO324680B1 (en)
NZ (1) NZ324739A (en)
PL (1) PL186621B1 (en)
PT (1) PT868184E (en)
WO (1) WO1997023219A1 (en)
ZA (1) ZA9610776B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2742660B1 (en) * 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques NOVEL FORMS OF EXTENDED RELEASE MICROGRANULES CONTAINING DILTIAZEM AS ACTIVE INGREDIENT
US6162463A (en) * 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
FR2790668B1 (en) * 1999-03-12 2002-07-26 D B F GRANULES CONTAINING A PLANT SUBSTANCE AND THEIR PREPARATION METHOD
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US7179483B2 (en) 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
FR2831546B1 (en) * 2001-10-31 2007-03-23 Atofina THERMOPLASTIC POLYMER MATERIAL FOR AUDIO AND / OR OPTICAL INFORMATION RECORDING MEDIA
CN1874764B (en) * 2003-10-10 2012-08-01 埃法尔姆公司 Sustained-release microgranules containing ginkgo extract and the process for manufacturing these
EP1698349A4 (en) * 2003-12-25 2009-12-16 Takeda Pharmaceutical Method of improving suitability for granulation
JP2005306778A (en) * 2004-04-21 2005-11-04 Basf Ag Sustained-release formulation and method for producing the same
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US8158156B2 (en) * 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
ITFI20110172A1 (en) 2011-08-08 2013-02-09 Valpharma Sa MULTIPARTICULATED FORMULATION WITH MODIFIED RELEASE OF DILTIAZEM HCL.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
IT1200217B (en) * 1986-09-30 1989-01-05 Valducci Roberto MEMBRANE FOR PHARMACEUTICAL AND INDUSTRIAL USE
DK173505B1 (en) * 1987-02-20 2001-01-15 Pharmatec Internat S R L Process for producing a slow release diltiazem pellet and using pellets thus prepared
JPH07552B2 (en) * 1987-11-06 1995-01-11 田辺製薬株式会社 Long-acting formulation
FR2623714B1 (en) * 1987-11-26 1990-04-20 Ethypharm Sa EXTENDED RELEASE FORM OF DILTIAZEM AND ITS MEDICINAL PRODUCT
FR2624732B1 (en) * 1987-12-21 1991-02-15 Synthelabo SUSTAINED RELEASE PHARMACEUTICAL FORMULATION
FR2630647B1 (en) * 1988-04-27 1991-08-16 Sanofi Sa DILTIAZEM MICROBALLS, PROCESS FOR PRODUCING THE SAME, AND SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5288505A (en) 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5376384A (en) 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
FR2742660B1 (en) * 1995-12-22 1998-04-03 Ethypharm Lab Prod Ethiques NOVEL FORMS OF EXTENDED RELEASE MICROGRANULES CONTAINING DILTIAZEM AS ACTIVE INGREDIENT

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006013431A1 (en) * 2004-07-29 2006-02-09 Pfizer Limited Stable controlled-release pharmaceutical formulation of eletriptan

Also Published As

Publication number Publication date
NO982738L (en) 1998-08-21
EP0868184A1 (en) 1998-10-07
US6660296B2 (en) 2003-12-09
CN1145488C (en) 2004-04-14
BG63770B1 (en) 2002-12-29
US6228395B1 (en) 2001-05-08
AU721949B2 (en) 2000-07-20
AR004410A1 (en) 1998-11-04
AU1198397A (en) 1997-07-17
ZA9610776B (en) 1997-06-30
PL327567A1 (en) 1998-12-21
IL125047A (en) 2003-05-29
KR19990076717A (en) 1999-10-15
EA199800593A1 (en) 1998-12-24
BR9612225A (en) 1999-07-13
DE69627880D1 (en) 2003-06-05
JP2000506500A (en) 2000-05-30
DK0868184T3 (en) 2003-08-25
HU224214B1 (en) 2005-06-28
PL186621B1 (en) 2004-02-27
CA2242224C (en) 2004-01-13
IL125047A0 (en) 1999-01-26
PT868184E (en) 2003-09-30
EA001721B1 (en) 2001-08-27
CA2242224A1 (en) 1997-07-03
ATE238798T1 (en) 2003-05-15
HUP9904129A3 (en) 2000-11-28
NZ324739A (en) 2000-01-28
DE69627880T2 (en) 2004-03-11
HUP9904129A2 (en) 2000-04-28
CN1207681A (en) 1999-02-10
HK1018400A1 (en) 1999-12-24
FR2742660A1 (en) 1997-06-27
NO324680B1 (en) 2007-12-03
NO982738D0 (en) 1998-06-12
BG102555A (en) 1999-02-26
EE04045B1 (en) 2003-06-16
FR2742660B1 (en) 1998-04-03
ES2198505T3 (en) 2004-02-01
US6383516B1 (en) 2002-05-07
KR100354054B1 (en) 2003-02-14
EE9800197A (en) 1998-12-15
WO1997023219A1 (en) 1997-07-03
EP0868184B1 (en) 2003-05-02
GEP20022629B (en) 2002-02-25

Similar Documents

Publication Publication Date Title
US6524620B2 (en) Diltiazem controlled release formulation and method of manufacture
CA1147651A (en) Sustained release pharmaceutical compositions
KR940000100B1 (en) Process for preparing pharmacentical preparating containing metoprolole
US6660296B2 (en) Sustained-release microgranules containing diltiazem as active principle
IE904091A1 (en) Sustained-release drug dosage units
AU1170499A (en) Spheroids, preparation method and pharmaceutical compositions
NZ201008A (en) Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
CS268819B2 (en) Method of particles production with effective substance's controlled loosening
PL184183B1 (en) Three-phase pharmaceutic form of constant-rate controllable release of amorphous active ingredient for administration once per day
US20040087578A1 (en) Pharmaceutical compositions containing carvedilol and hydrochlorothiazide
IE48891B1 (en) A pharmaceutical preparation comprising a cardiac glycoside with a polymer coating,and a process for preparation thereof
US6733789B1 (en) Multiparticulate bisoprolol formulation
US7063864B1 (en) Morphine sulphate microgranules, method for preparing same and compositions containing same
CA2417887C (en) Particulate composition of eletriptan
EP1143963B1 (en) Multiparticulate bisoprolol formulation
PL192648B1 (en) Pharmaceutical with controlled releose containing inhibitor ace as an active substance
JPH04234812A (en) Granule for long-acting pharmaceutical preparation
EP0447168A2 (en) Long acting granular pharmaceutical composition
KR20030076634A (en) Medicinal composition
US5980952A (en) Pharmaceutical composition for the programmed release of dexfenfluramine
US20040185099A1 (en) Multiparticulate bisoprolol formulation
PL199813B1 (en) Prolonged release oral solid pharmaceutical acebutolol preparation and method of its production
IE910828A1 (en) Long acting granular pharmaceutical composition

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: ETHYPHARM, FRANCE

Free format text: CHANGE OF NAME;ASSIGNOR:LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARM;REEL/FRAME:018761/0135

Effective date: 20010607

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: BIOVAIL LABORORATORIES INTERNATIONAL, S.R.L., BARB

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LABORATORIES DES PRODUITS ETHIQUES ETHYPHARM;REEL/FRAME:019597/0378

Effective date: 20061106

AS Assignment

Owner name: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL

Free format text: SECURITY AGREEMENT;ASSIGNORS:BIOVAIL INTERNATIONAL LABORATORIES SRL;BIOVAIL INTERNATIONAL LABORATORIES (BARBADOS) SRL;REEL/FRAME:025084/0022

Effective date: 20100928

AS Assignment

Owner name: BIOVAIL INTERNATIONAL LABORATORIES (BARBADOS) SRL,

Free format text: PATENT SECURITY RELEASE AGREEMENT;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS LLC;REEL/FRAME:025950/0073

Effective date: 20110308

Owner name: BIOVAIL INTERNATIONAL LABORATORIES SRL, BARBADOS

Free format text: PATENT SECURITY RELEASE AGREEMENT;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS LLC;REEL/FRAME:025950/0073

Effective date: 20110308

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: VALEANT INTERNATIONAL (BARBADOS) SRL, BARBADOS

Free format text: CHANGE OF NAME;ASSIGNOR:BIOVAIL LABORATORIES INTERNATIONAL SRL;REEL/FRAME:026404/0095

Effective date: 20110308

AS Assignment

Owner name: CHANTILLY BIOPHARMA LLC, VIRGINIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VALEANT INTERNATIONAL (BARBADOS) SRL;REEL/FRAME:026865/0563

Effective date: 20110408

AS Assignment

Owner name: VALEANT INTERNATIONAL BERMUDA, BERMUDA

Free format text: CHANGE IN NAME AND COUNTRY OF INCORPORATION;ASSIGNOR:VALEANT INTERNATIONAL (BARBADOS) SRL;REEL/FRAME:028757/0052

Effective date: 20120703

FPAY Fee payment

Year of fee payment: 12